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Retrospective on U.S. Health Risk Assessment:
How Others Can Benefit*
Dennis J. Paustenbach**
Introduction
As broadly defined, risk assessment can be used to predict the
likelihood of many unwanted events, including industrial explosions,
workplace injuries, failures of machine parts, natural catastrophes, injury
or death from an array of voluntary activities, diseases, natural causes,
life-style or others. 1 Thus, an extraordinary number of publications
on risk assessment deal with a wide range of topics.2
Health risk assessment, however is a separate and distinct discipline
which uses toxicology data collected from animal studies and human
epidemiology, combined with information about the degree of
exposure, to quantitatively predict the likelihood that a particular
adverse response will be seen in a specific human population. 3 The
assessment of toxicology data to predict health risks is not entirely
new;4 the risk-assessment process has been used by agencies for
* This paper is based on a presentation made at the 1st International Ecological
Risk Assessment Conference, Melbourne, Australia.
** Dr. Paustenbach is Chief Technical Officer of ChemRisk®, a division of
McLaren/Hart Environmental Engineering. He received his B.S. (Chemical
Engineering) from the Rose-Human Institute of Technology, a M.S. (Environmental
& Industrial Health) from the University of Michigan, a M.S. (Counseling
Psychology) from Indiana State University and his Ph.D. (Environmental
Toxicology) from Pudue University.
1 Societal Risk Assessment. How Safe is Safe Enough? (Richard C. Schwing &
William A. Albers Jr., eds. 1980); Christopher F. Wilkinson, Risk Assessment and
Regulatory Policy, 1 Comments Toxicol. 1 (1987); Richard Wilson & Edmund
A.C. Crouch, Risk Asessment and Comparisons: An Introduction, 236 Science 267(1987); Paul Slovic, Perception of Risk, 236 Science 280 (1987); Ben J. Wattenberg,
The Good News is the Bad News is Wrong (1984) and W. Kip Viscusi, Fatal
Tradeoffs: Public and Private Responsibilities for Risk (1992).
2 Dennis J. Paustenbach, The Risk Assessment of Environmental Hazards: A
Textbook of Case Studies (1989).
3 Id. and National Academy of Sciences (NAS), Science and Policy in Risk
Assessment (1994).
4 Carol S. Weil, Statistics Versus Safety Factors and Scientific Judgement in the
Evaluation of Safetyfor Man, 21 Toxicol. Appl. Pharmacol. 454 (1972) and William
W. Lowrance, Of Acceptable Risk (1976).
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almost 40 years, most notably within the U.S. Food and Drug
Administration (FDA). 5  However, the difference between
assessments performed in the 1950's and 1960's and those performed
in the 1980's and 1990's is the incorporation of a complex and
quantitative exposure assessment. With the emergence of quantitative
methods, risk-assessment models can better estimate the probability
that a specific adverse effect will occur over a wide range of doses. 6
Since 1980, many environmental regulations and some occupational
health standards have, at least in part, been based on the results of low-
dose extrapolation models and exposure assessments.7 For example,
risk-assessment methodologies have been used to set standards for
pesticide residues, food additives, pharmaceutical agents, drinking
water, soil and ambient air, as well as exposure limits for contaminants
found in indoor air, consumer products and other media.8 Risk
managers increasingly rely on risk assessments to decide whether a
broad array of environmental risks are significant or trivial, an
important task since over 300 of about 5,000 chemicals routinely used
in industry have been labelled carcinogens as a result of animal
studies. 9 Risk assessment has become prominent in both the U.S. and
5 Arnold J. Lehmann & 0. Garth Fitzhugh, 100 Fold Margin of Safety, 18 Q.
Buff. Assoc. Food Drug Off. U.S. 33 (1954); Michael L. Dourson & Jerry F. Stara,
Regulatory History and Experimental Support o Uncertainty (Safety Factors), 3
Regul.Toxicol. Pharmacol. 224 (1983); Joseph V. Rodricks, Origins of Risk
Assessment in Food-Safety Decision-Making, 7 Am. Coil. Toxicol. 539 (1989) and
U.S. Department of Health and Human Services, Determining Risks to Health:
Federal Policy and Practice (1986).
6 Paustenbach, supra note 2.
7 Ian C. Munro & Daniel R. Krewski, Risk Assessment and Regulatory Decision-
making, 19 Food Cosmet. Toxicol. 549 (1981); Peter W. Preuss & A. M. Ehrlich,
The Environmental Protection Agency's Risk Assessment Guidelines, 37 J. Air
Pollut. Control Assoc. 7841 (1987); Joseph V. Rodricks, Susan M. Brett & Grover C.
Wrenn, Significant Risk Decisions in Federal Regulatory Agencies, 7 Regul. Toxicol.
Pharmacol. 307 (1987) and Center for Risk Analysis, Historical Roots of Health Risk
Assessment (1994).
8 Center for Risk Analysis, supra; Dennis J. Paustenbach, Health Risk
Assessments _Opportunities and Pitfalls, 14 Colum. J. Environ. Law 379-410 (1989);
Executive Office of the President, Regulatory Program of the U.S. Government, April
1, 1990 to March 31, 1991 (1991) and Carnegie Commission on Science,
Technology, and Government, Risk and the Environment, Improving Regulatory
Decision Making (1993).
9 Bruce N. Ames, Renae Magaw & Lois S. Gold, Ranking Possible Carcinogenic
Hazards, 236 Science 271 (1987); Bruce N. Ames & Lois S. Gold, Too Many
Rodent Carcinogens: Mitogenesis Increases Mutagenesis, 249 Science 970 (1990);
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Canada because it was seen as better than prior attempts to make
decisions from volumes of toxicology and epidemiology data collected
over the past 40 years. 10
In 1980, for example, the U.S. Supreme Court considered the
results of risk assessment to conclude that more stringent regulation of
benzene was unwarranted unless it lowered significant risks,11 but the
challenge of deciding which risks are significant faces legislators and
regulators worldwide. The practice of risk assessment has helped
illustrate that decisions about industrial and agricultural practices in
nearly any country in some circumstances can adversely affect the
health of people and the environment elsewhere. For example, the
destruction of the rain forests in South America or changes in the ozone
layer in Antarctica are believed to influence the climate, in North
America and Europe. To help insure that the most important
environmental hazards are tackled ahead of lesser ones, it would be
useful if all countries had a consistent and objective approach to
assessing environmental risks so that political or social pressures were
not given much weight. 12
Health Risk Assessment: A Brief History
The origin of health risk assessment, in its most basic form, can be
traced back to that of early humans. When early man recognized that
wildlife represented a source of food when edible plants were not
available, primitive risk assessors weighed the hazard of being mauled
Bruce N. Ames & Lois S. Gold, Comparing Synthetic to Natural Chemicals is
Essential for Perspective in 'Risk Assessment, "Risk Analysis (1993); Bruce N. Ames
& Lois S. Gold, Environmental Pollution and Cancer: Some Misconceptions in
Phantom Risk. Scientific Inference and the Law, 153 (K.R. Foster, D.E. Bernstein, &
P.W. Huber, eds. 1993); Joseph V. Rodricks, Calculated Risks (1992); Terry Yosie,
How Risk Assessments Are Used in the Federal Government, 21 Environ. Sci.
Technol. 526 (1987) and Frank A. Young, Risk Assessment: The Convergence of
Science and the Law, 7 Regul. Toxicol. Pharmacol. 179 (1987).
10 NAS, Risk Assessment in the Federal Government: Managing the Process (1983);
NAS, supra note 3; William Ruckelshaus, Risk, Science, and Democracy, 1(3) Sci.
& Tech. 19 (1985) and Donald Barnes, What Should We Do Now? 11 Environ.
Toxicol. Chem. 729 (1992).
11 Industrial Union Dept., AFL-CIO v. Am. Petroleum Institute, 448 U.S. 607
(1980) and John D. Graham, Laura C. Green & Marc J. Roberts, In Search of Safety:
Chemicals and Cancer Risks 80-114 (1988).
12 U.S. Environmental Protection Agency (EPA), Credible Science; Credible
Solutions (1992).
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by a wild animal, which they hoped to kill and eat, versus the benefit of
thwarting starvation. The historical record does not permit us to know
how well early humans balanced this risk-benefit relationship; however,
it is safe to assume that those who failed to successfully conduct these
assessments fared poorly.
A thoughtful review of the history of risk analysis has been
published. 13 In it, the authors noted that perhaps the world's first
professional risk assessors were the Asipu people who lived in the Tigris-
Euphrates valley about 3,200 B.C. According to Covello and
Mumpower, 14 their primary function was to serve as consultants for
risky, uncertain or difficult decisions. For risky ventures such as a
proposed marriage arrangement or a suitable building site, the Asipu
would identify the important dimensions of the problem, identify
alternative actions and collect data on the likely outcomes of each
alternative. The best available data from their perspective were signs
from the gods, which the priest-like Asipu were especially qualified to
interpret. After an analysis of benefits and costs of each alternative was
completed, the Asipu would recommend to their client the most
favorable alternative, etched upon a clay tablet.
The similarities between the practices of modern risk assessors and
those of ancient Babylon underscore the historical concerns of society
regarding the problems of risk and appreciation of cause and effect
relationships in everyday life. By the 16th to 18th Centuries, the basis
for the current approach to health risk assessment was established,
including a sensitivity to the importance of exposure and response.
During the early decades (1900-1940) of the 20th Century, qualitative
understanding of health risk assessment improved as health scientists
and factory managers learned of the hazards of occupational exposure
to the more than 300 chemicals then routinely used in the
workplace. 15
The emergence of modern health risk assessment can be traced to
about 1975. Since then, the considerable knowledge gained from
scientists in many disciplines has been slowly transferred to
13 Vincent T. Covello & Jerry Mumpower, Risk Analysis and Risk Management:
An Historical Perspective, 5 RiskAnal. 103 (1985).
14 Id.
15 Id. and Hunter's Diseases of Occupation (P. A. Raffle et al., eds. 1987).
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environmental regulators, who often take a lead role in formulating
improvements in various risk assessment methods. 16 For example,
nearly two dozen guidance documents (about 5,000 pages) on how risk
assessments should be conducted have been written by the U.S.
Environmental Protection Agency (EPA) since 1986. Unfortunately, as
EPA standardized the process, assessments often became too inflexible
to properly characterize the more likely risks. Specifically, most
regulatory attempts to standardize assessment methods have
introduced several levels of conservatism because such assessments have,
for the sake of public safety, been structured to over-estimate true
risks. 17
The Debate on the Appropriateness of Risk Assessment
Risk assessment, by its very nature, is a process whereby the
magnitude of a specific risk is characterized so that decision makers can
conclude whether the potential hazard is sufficiently great that it needs
to be managed or regulated. 18 Therefore, before deciding to conduct
16 Dennis J. Paustenbach, A Survey of Health Risk Assessment, in The Risk
Assessment of Environmental and Human Health Hazards: A Textbook of Case
Studies 27 (D. J. Paustenbach, ed. 1989).
17 Albert L. Nichols & Robert J. Zeckhauser, The Perils of Prudence: How
Conventional Risk Assessments Distort Regulations, 8 Regul. Toxicol. Pharmacol. 61
(1988); Dennis J. Paustenbach et al., The Current Practice of Health Risk
Assessment: Potential Impact on Standards for Toxic Air Contaminants, 40 J. Air
Waste Mgt. Assoc. 1620 (1990); Dennis J. Paustenbach et al., Recent Developments
on the Hazards Posed by 2,3,7,8-Tetrachlordibenzo-p-dioxin in Soil. Implications
for Setting Risk-Based Cleanup Levels at Residential and Industrial Sites, 36 J.
Toxicol. Environ. Health 103 (1992); Dennis J. Paustenbach, Important Recent
Advances in the Practice of Health Risk Assessment: Implications for the 1990s, 10
Regul. Toxicol. Pharm. 204 (1989); Brent L. Finley & Dennis J. Paustenbach, The
Benefits of Probabilistic Exposure Assessment: Three Case Studies Involving
Contaminated Air, Water, and Soil, 14 Risk Anal. 53 (1994); Brent Finley et al.,
Recommended Distributions for Exposure Factors Frequently Used in Health Risk
Assessment, 14 Risk Anal. 533 (1994); Neil C. Hawkins, Conservatism in
Maximally Exposed Individual Predictive Exposure Assessments: A First-Cut
Analysis, 14 Regul. Toxicol. Pharm. 107 (1991); David E. Burmaster & Paul D.
Anderson, Principles of Good Practice for the Use of Monte Carlo Techniques in
Human Health and Ecological Risk Assessments, 14 RiskAnal. 477 (1994); Terie L.
Copeland et al., Comparing the Results of a Monte Carlo Analysis with EPA's
Reasonable Maximum Exposed Individual: A Case Study of a Former Wood
Treatment Site, 18 Regul. Toxicol. Pharm. 275 (1993) and Terie L. Copeland et al.,
Use of Monte-Carlo Techniques to Understand the Conservatism in California s
Approach to Assessing Air Toxics, J. Air Waste Mgmt. Assn. (1994).
18 Ellen K. Silbergeld, Five Types of Ambiguity: Scientific Uncertainty in Risk
Assessment, 4 Haz. Waste Haz. Matls. 139 (1987) and Ellen K. Silbergeld, Risk
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such analyses, one must concede that some level of risk can be deemed
acceptable; that is, a risk-benefit balance can be found. 19
Although many in society are concerned about the uncertainty and
variability of assessment processes used in today's environmental
decision making, the public can take solace in the fact that new and
better information concerning the uptake and metabolism of toxins is
continually being developed, the degree of exposure and the likelihood
that an adverse effect will occur at a specific dose. Nonetheless, it is true
that chemical hazards are not, and may never be, completely eliminated
when decisions are based on a risk assessment. For this reason, some
nations, including Germany, Sweden and others, have traditionally
regulated chemicals to reduce emissions and exposure to the lowest
level achievable using engineering controls or to impose a ban, raising
yet another set of risk and technology issues. Also, an approach can be
problematic in that it diverts financial resources that might be used to
address other risks such as AIDS or to provide immunization programs.
Reducing health risks to levels that are "as low as reasonably
achievable" (ALARA) or requiring the use of the "best available
technology" (BAT) can produce significant reductions in the degree of
exposure, but either policy has two possible shortcomings. First,
adopting an ALARA or BAT approach can be costly and may not result
in an appreciable overall benefit (reduction of risk) to society.2 0
Second, a reliance on banning may not ensure that a significant or even
measurable level of risk reduction will occur.2 1 History demonstrates
that banning chemicals may well eliminate one risk, but often this
hazard is replaced by another and the financial sacrifice is often not to
the overall benefit of society. For example, chemical substitutions, as in
Assessment: The Perspective and Experience of the U.S. Environmentalists, 101
Environ. Health Persp. 100 (1993).
19 Aaron Wildavsky, Searching for Safety (1991); Thomas B. Starr, Risk
Management, Assessment, and Acceptability, 5 Risk Anal. 97 (1985); Richard
Zeckhauser & William K. Viscusi, Risk Within Reason, 248 Science 559 (1990);
Seymour Friess, VIII Risk Assessment; Historial Perspectives in Drinking Water and
Health 3 (1987); Stephen Breyer, Breaking the Vicious Circle: Towards Effective Risk
Regulation (1994) and Rae Zimmerman, Social Equity and Environmental Risk, 13
RiskAnal. 649 (1993).
20 Dennis J. Paustenbach, Jousting with Environmental Windmills, 13 Risk Anal.
13 (1993).
21 Francine Laden & George M. Gray, Toxics Use Reduction: Pro and Con, 4 Risk
213 (1993).
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the case of saccharin and Nutrasweet®, may raise new uncertainties
about other risks to health. In an ideal world, the costs of decisions
concerning risk reduction should be weighed against the benefits of
applying the same resources to reduce other important risks such as
adequate medical care for all citizens or immunization. 22 However, no
one has yet determined how to distribute limited financial resources
optimally between very different portions of the U.S. budget dealing
with, e.g., education, space engineering or the military.
Improving the Practice of Risk Assessment
Risk assessment has (by convention) been separated into four
subdisciplines: hazard identification, dose-response assessment,
exposure assessment and risk characterization. 2 3 This has been called
the "risk assessment paradigm." Hazard identification is the first and
most easily recognized step in risk assessment. It is the process of
determining whether exposure to an agent could (at any dose) cause an
increase in the incidence of adverse health effects in humans or wildlife.
Dose-response evaluations define the relationship between the dose of
an agent and the probability of a specific adverse effect in laboratory
animals. Exposure assessment quantifies the uptake of xenobiotics from
the environment by any combination of oral, inhalation and dermal
routes of exposure. The most important part of an assessment, risk
characterization, summarizes and interprets the information collected
from previous activities and identifies the limitations and the
uncertainties in risk estimates.24
Nearly twenty years of U.S. experience have taught scientists a great
deal about how to perform each step in risk assessment more efficiently
and accurately. 2 5 With the ongoing and accelerating application of
22 Graham, Green & Roberts, supra note 11; Wattenberg, supra note 1; Viscusi,
supra note 1; Wildavsky, supra note 19; Benjamin J. O'Keefe, Shooting Ourselves in
the Foot (1985); George M. Gray & John D. Graham, Risk Assessment and Clean
Air Policy, 10 J. PolicyAnal. & Mgmt. 286 (1991); John D. Graham, Harnessing
Science for Environmental Regulation (1991) and Michael Gough, How Much
Cancer Can EPA Regulate Anyway? 10 RiskAnal. 1 (1990).
23 NAS, supra note 10 and NAS, supra note 3.
24 Preuss & Ehrlich, supra note 7 and NAS, supra note 3.
25 Paustenbach, supra note 17, Finley et al., supra note 17, Copeland et al., supra
note 17, Robert L. Sielken, Some Issues in the Quantitative Modeling Portion of
Cancer Risk Assessment, 5 Regul. Toxicol. Pharm. 175 (1985); Thomas B. Starr &
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risk analyses worldwide, the time is ideal to adopt many improvements
to risk assessment that have been identified which could significantly
advance the usefulness of risk assessment in the twenty-first century.
Hazard Identification
We have learned a great deal about how U.S. regulatory agencies
might better have conducted the hazard-identification process over the
past ten to twenty years, and many possible improvements are
discussed here (Table 1).26 For example, we need not consider all
Raymond B. Buck, The Importance of Delivered Dose in Estimating Low-Dose
Cancer Risk for Inhalation Exposure to Formaldehyde, 4 Fund. Appl. Toxicol. 740
(1984); Melvin E. Andersen, Quantitative Risk Assessment and Chemical
Carinogens in Occupational Environments, 3 Appl. Ind. Hyg. 267 (1991); Melvin
E. Andersen et al., Physiologically Based Pharmacokinetic Modeling with
Dichloromethane, Its Metabolite, Carbon Monoxide, and Blood Carboxy-
hemoglobin in Rats and Humans, 108 Toxicol. Appl. Pharmacol. 14 (1991); J. Ashby
ct al., A Scheme for Classifying Carcinogens, 12 Regul. Toxicol. Pharm. 270 (1990);
Frederick Y. Bois, Lauren Zeise & Thomas N. Tozer, Precision and Sensitivity
Analysis of Pharmacokinetics Models for Cancer Risk Assessment:
Tetrachloroethylene in Mice, Rates, and Humans, 102 Toxicol. Appl. Pharmacol.
300 (1990); Kenneth T. Bogen, Risk Extrapolation for Chlorinated Methanes as
Promoters vs. Initiators of Multistage Carcinogenesis, 15 Fund. Appl. Toxicol. 536
(1990); Kenneth T. Bogen, Cell Proliferation Kinetics and Multistage Cancer Risk
Models, 81 J. Natl. Cancer Inst. 267 (1989); David E. Burmaster & Karl von
Stackelberg, Using Monte Carlo Simulations in Public Health Risk Assessments:
Estimating and Presenting Full Distributions of Risk, 1 J. Expos. Anal. Environ.
Epid. 491 (1991); Suresh H. Moolgavkar, Anup Dewanji & David J. Venzon, A
Stochastic Two-Stage Model for Cancer Risk Assessment: The Hazard Function and
the Probability of Tumors, 8 Risk Anal. 383 (1988); Samuel M. Cohen, E.M.
Garland & Leon B. Ellwein, Cancer Enhancement by Cell Proliferation, 374 Prog.
Clin. Biol. Res. 213 (1992); J. Huff & J. Haseman, Long-Term Chemical
Carcinogenesis Experiments for Identifjing Potential Human Cancer Hazards:
Collective Database of the National Cancer Institute and National Toxicology
Program (1976-1991), 96 Environ. Health Persp. 23 (1991); W. Gary Flamm & Lois
D. Lehman-McKeeman, The Human Relevance of the Renal Tumor-Inducing
Potential of D-Limonene in Male Rats: Implications for Risk Assessment, 13 Regul.
Toxicol. Pharm. 70 (1991); Rory B. Connolly et al., A Biologically-Based Risk
Assessment Strategy for Inhaled Formaldehyde, 4 Comments Toxicol. 269 (1992);
Gary Goodman & Richard Wilson, Quantitative Prediction of Human Cancer Risk
from Rodent Carcinogenic Potencies: A Closer Look at the Epidemiological
Evidence for Some Chemicals Not Definately Carcinogenic in Humans, 14 Regul.
Toxicol. Pharm. 118 (1991) and Robert A. Squire, Ranking Animal Carcinogens: A
Proposed Regulatory Approach, 214 Science 877 (1981).
26 Huff & Haseman, supra; Squire, supra; Robert C. Barnard, Robert J. Moolenaar
& Donald E. Stevenson, IARC and HHS Lists of Carcinogens: Regulatory Use
Based on Misunderstanding of the Scope of Purposes of the Lists, 9 Regul. Toxicol.
Pharm. 81 (1989); Robert C. Barnard, Some Regulatory Definitions of Risk:
Interaction of Scientific and Legal Principles, 11 Regul. Toxicol. Pharm. 201 (1990);
James Huff, Joseph Haseman & David Rail, Scientific Concepts, Value, and
Significance of Chemical Carcinogenesis Studies, 31 Ann. Rev. Pharm. & Toxicol.
621 (1991); Byron E. Butterworth, A Review of Mechanisms of Carcinogenesis
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animal carcinogens as posing an equally serious human hazard because
we now know that carcinogens vary dramatically in their carcinogenic
and/or mutagenic potency.2 7 Some carcinogens, e.g., ethylene oxide,
are mutagenic at low doses in every in vitro and in vivo test, while
others, e.g., the dioxins and cyclodienes, are potent carcinogens but are
not mutagenic or genotoxic in any of these tests.28 Weak carcinogens,
e.g., saccharin, may require a dose 10-million-fold greater than for
potent carcinogens, e.g., aflatoxin, to produce the same response in
animals. 2 9 In short, many factors including tumor type, species,
metabolism, pharmacokinetics, mechanism of action and the
epidemiological experience all need to be considered when attempting
to predict whether a specific chemical poses a significant hazard to
humans at doses to which they might reasonably be exposed.3 0
This helps explain why more than 400 chemicals have been found in
animal studies to produce tumors, yet fewer than twenty are known
human carcinogens. 3 1 Even after accounting for the typical
epidemiology shortcomings, it is clear that some, if not many, rodent
carcinogens do not pose an equivalent cancer hazard in humans.3 2
Although it is plausible that some carcinogens may pose a greater
(1994); Byron E. Butterworth & Thomas Slaga, Nongenotoxic Mechanisms in
Carcinogenesis (Banbury Report No. 25 1987) and Byron E. Butterworth,
Consideration of Both Genotoxic and Nongenotoxic Mechanisms in Predicting
Carcinogenic Potential 239 Murat. Res. 117 (1990).
27 Ames, Magaw & Gold, supra note 9; Ames & Gold, supra note 9; Bruce C.
Allen, Kenny S. Crump & Annette M. Shipp, Correlation Between Carcinogenic
Potency of Chemicals in Animals and Humans, 8 RiskAnal. 531 (1988) and John
Ashby & Raymond W. Tennant, Definitive Relationships Among Chemical
Structure, Carcinogenicity, and Mutagenicity for 301 Chemicals Tested by the U.S.
NTP, 257 Mutat. Res. 229 (1991).
28 Gary M. Williams & John H. Weisburger, Chemical Carcinogenesis, in Casarett
and Doull's Toxicology- The Basic Science of Poisons 127 (4th ed. M. D. Amdur, J.
D. Doull & C. D. Klaassen, eds. 1991).
29 Ames & Gold (1990), supra note 9; Ames & Gold (1993), supra note 9 and
Williams & Weisburger, supra.
30 Bogen, supra note 25; Squire, supra note 25; Butterworth, supra note 26 and
Williams & Weisburger, supra note 28.
31 Ames, Magaw & Gold, supra note 9; Ames & Gold (1990), supra note 9 and
Ames & Gold (1994), supra note 9.
32 Connolly et al., supra note 25; Jack Moore, Renate Kimbrough & Michael
Gough, The Dioxin TCDD: A Selective Study of Science and Policy (1994) and
Renate D. Kimbrough, How Toxic is 2,3,7,8-TCDD to Humans? 30 J. Toxicol.
Environ. Health 261 (1990).
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human hazard than that suggested by rodent studies, there are few
examples where appropriate animal tests were conducted.
Table 1
Lessons Learned in the U. S. Regarding
How to Improve the Conduct of Health Risk Assessment
Hazard Identification Dose-Response Exposure Risk
Assessment I Assessment Characterization
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The same generalization applies to developmental and reproductive
toxicants. 33 Unfortunately, most human exposure is not to a single
33 E. Marshall Johnson et al., Use of the Adult Developmental Relationship in Pre-
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chronic toxicant, so the complexities of potentiation, antagonism and
synergy must also be considered when the simultaneous uptake of
substantial amounts of various toxicants occurs. 34 Clearly, in light of
the hundreds of industrial chemicals to which we are daily exposed, the
challenge to regulators is to identify toxicants for which exposure
should be limited.
As a result of knowledge gained during 1975-95, the first twenty
years of health risk assessment, it has become clear that most animal
carcinogens (at some dose) will probably pose a human cancer hazard.
However, actual human cancer risk at very low doses remains unclear
and will continue to be debated for many years.3 5 The criteria by
which a risk assessor determines that a chemical could pose a significant
carcinogenic or developmental threat to humans is based on animal
studies and consideration of at least six factors. For carcinogens, these
include the number of animal species affected, the number and types of
tumors occurring in them, the dose (relative to the acute toxic dose) at
which they are affected, the dose/response relationship, and the
genotoxicity of the chemical. 3 6 For developmental toxicants, the key
issues in hazard identification are similar to those for carcinogens and
include the number of species affected, the severity of effects, the slope
of the dose-response curve and the relationship between the dose which
affects the mother compared to that affecting the offspring.37
Screening for Developmental Hazards, 7 Terato. Carcin. Mutagen. 273 (1987); E.
Marshall Johnson, A Two Tier System for Developmental Toxicity Evaluations Based
on Consideration of Exposure and Effect Relationships, 35 Teratol. 405 (1987) and
E. Marshall Johnson, Cross-Species Extrapolations and the Biologic Basis for Safety
Factor Determinations in Developmental Toxicology, 8 Regul. Toxicol. Pharm. 22
(1988).
34 Daniel Krewski, Todd Thorslund & James Withey, Carcinogenic Risk
Assessment of Complex Mixtures, 5 Toxicol. Ind. Health 851 (1989); Daniel
Krewski & Richard D. Thomas, Carcinogenic Mixtures, 12 Risk Anal. 105 (1992)
and Ralph L. Kodell, Daniel Krewski & Jan M. Zielinski, Additive and Multiplicative
Relative Risk in the Two-Stage Clonal Expansion Model of Carcinogenesis, 11 Risk
Anal. 483 (1991).
35 Allen, Crump & Shipp, supra note 27; Ashby & Tennant, supra note 27 and
Williams & Weisburger, supra note 27.
36 Squire, supra note 25; Butterworth, supra note 26 and Williams & Weisburger,
supra note 28.
37 Johnson et al., supra note 33; Ralph L. Kodell et al., Mathematical Modeling of
Reproductive and Developmental Toxic Effects for Quantitative Risk Assessment, 11
RiskAnal. 583 (1991); William L. Hart et al., Evaluation of Developmental Toxicity
Data: A Discussion of Some Pertinent Factors and a Proposal, 8 Risk Anal. 59
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Over the past two decadess, scientists have also learned not to place
equal weight on all data. Regulators, for example, need to resist the
temptation to emphasize any data that suggests that a chemical poses a
carcinogenic or developmental hazard but put little weight on any that
suggests a failure to cause such effects at environmentally relevant
exposures. This approach has heretofore been considered prudently
health-protective. Yet, it is not scientific, nor is it necessarily in the
public's best interest. 38 For example, extraordinary confidence has
sometimes been placed on studies suggesting that a chemical may pose
a particular hazard with modest consideration of the study's quality.3 9
During the 1990's, the scientific community and most regulators
have come to accept that not all data are equal, and that only data of
similar quality should be judged equally.4 0 In the U.S., this is known
(1988); Rhoda Wang & Bernard A. Schwetz, An Evaluation System for Ranking
Chemicals with Teratogenic Potential, 7 Terato. Carcin. Mutagen. 133 (1987) and
E. Marshall Johnson, A Case Study of Developmental Toxicity Risk Estimation
Based on Animal Data: The Drug Bendectin, in The Risk Assessment of
Environmental Hazards: A Textbook of Case Studies 711 (D. J. Paustenbach, ed.
1989).
38 See Slovic, supra note 1; Adam M. Finkel, Edifying Presentation of Risk
Estimates: Not as Easy as It Seems, 10 J. Policy Anal. Mgmt. 296 (1991); David E.
Burmaster & Robert N. Harris, The Magnitude of Compounding Conservatism in
Superfund Risk Assessments, 13 Risk Anal. 131 (1993); Richard W. D'Souza &
Harold Boxenbaum, Physiological Pharmacokinetic Models: Some Aspects of
Theory, Practice and Potential, 4 Toxicol. Ind. Health 151 (1988); Richard Reitz et
al., Physiologically-Based Pharmacokinetic Modeling with Methylchloroform:
Implications for Interspecies, High Dose/Low Dose, and Dose-Route
Extrapolations, 95 Toxicol. App. Pharm. 185 (1988); David G. Hoel, Norman L.
Kaplan & Marshall W. Anderson, Implication of Nonlinear Pharmacokinetics onRisk Estimation in Carcinogenesis, 291 Science 1032 (1983); Richard H. Reitz,Melvin Andersen & Michae[ Gargas, A PB-PK Model fr Vinyl Chloride, Toxicol.
App. Pharm. (in review 1995); Robert C. Spear et al., Modeling BenzenePharmacokinetics Across Three Sets of Animal Data: Parametric Sensitivity and RiskImplic ti ns, 11 RiskAnal. 641 (1991); Christopher Whipple, Nonpessimistic Risk
Assessment and De Minimus Risk as Risk Management Tools, in The RiskAssessment of Environmental and Human Health Hazards: A Textbook of CaseStudies 1105 (D. J. Paustenbach, ed.1989); D. Zilberman et al., The Economics ofPesticide Use and Regulation, 253 Science 518 (1993) and Charles T. Rubin, TheGreen Crusade: Rethini ng the Roots of Environentalism (1994).39 See Rodricks, supra note 9; Manfred S. von Wittenau, Strengths andWeaknesses of Long-Term Bioassays, 7 Regul. Toxicol. Pharm. 113 (1988); Bruce N.Ames, Pesticides, Risk and Applesauce, 244 Science 755 (1989); Phillip H. Abelson,Exaggerated Carcinogenicity of Chemicals, 256 Science 160 (1992) and John Barr,
Design and Interpretation of Bioassays for Carcinogenicity, 7 Regul. Toxicol. Pharm.
422 (1988).
40 See von Wittenau, supra; Ames, supra; Abelson, supra and Barr, supra. See
also, Barnard, Moolenaar & Stevenson, supra note 26; Barnard, supra note 26;
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as the "weight-of-evidence" approach. It represents an important
refinement and is applicable not only to hazard identification, but also
to exposure and dose-response evaluations. One benefit of using a
"weight-of-evidence" approach is that it minimizes the possibility that
huge sums of money will be spent to conduct several high quality
toxicity studies, only to have the results refuted by one or two poor
ones. 4 1 This approach has been embraced by many environmental
agencies outside the U.S. Some of the best examples where an agency
attempted to use a weight-of-evidence approach, coupled with
understanding of the mechanism of action, include d-limonene,
4 2
formaldehyde, 4 3 NTA,44 methylene chloride,4 5 and chloroform.
4 6
Dose-Response Assessments
A dose-response evaluation usually requires an extrapolation from
the generally high doses administered to experimental animals, or
exposures reported in occupational studies, to the exposures expected
from human contact with the agent in the environment (Figure 1).
As we enter the mid-1990's, it is clear that the most uncertain
aspect of chemical assessments, especially carcinogens, is the low-dose
extrapolation. Although perhaps humbling, most toxicologists agree
that they are limited in ability to estimate the risks associated with
Huff, Haseman & Rail, supra note 26; Butterworth, supra note 26; Butterworth &
Slaga, supra note 26; and Butterworth, supra note 26; Allen, Crump & Shipp, supra
note 27; Ashby & Tennant, supra note 27; Williams & Weisburger, supra note 28;
Moore, Kimbrough & Gough, supra note 32; Kimbrough, supra note 32; references
supra notes 33 and 34; Kodell et al., supra note 37; Hart et al., supra note 37;
Wang & Schwetz, supra note 37; Johnson, supra note 37; EPA, supra note 39;
Finkel, supra note 38; Burmaster & Harris, supra note 38; D'Souza & Boxenbaum,
supra note 38; Reitz et al., supra note 38; Hoel, Kaplan & Anderson, supra note 38;
Reitz, Andersen & Gargas, supra note 38; Spear et al., supra note 38; Whipple,
supra note 38; Zilberman et al., supra note 38 and Rubin, supra note 38.
41 Barr, supra note 39; EPA, Science Advisory Board, Unfinished Business (1988);
EPA, Science Advisory Board, Reducing Risk. Setting Priorities and Strategies for
Environmental Protection (1990) and EPA, Science Advisory Board, Safeguarding the
Future (1991).
42 Flamm & Lehman-McKeeman, supra note 25.
43 Connolly et al., supra note 25.
44 Robert L. Anderson & Charles L. Alden, Risk Assessment for Nitrilotriacetic
Acid (NTA) in The Risk Assessment of Environmental and Human Health Hazards:
A Textbook of Case Studies 390 (D. J. Paustenbach, ed. 1989).
45 Andersen, supra note 25.
46 Rory A Corley et al., Development of a Physiologically-Based Pharmacokinetic
Model for Chloroform, 103 Toxicol. Appl. Pharm. 512 (1990).
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typical levels of environmental exposure based on results of standard
rodent bioassays.4 7 There are many reasons why this is so. First, we do
not fully understand all of the possible mechanisms of action for
carcinogens. 4 8 Second, the doses at which we conduct the animal tests
are so high that they often produce effects that would not occur at the
doses to which people are exposed. 4 9 Third, there are usually
significant differences between animals and humans with respect to the
rate at which chemicals are metabolized, distributed and excreted.
Fourth, the delivered dose to specific target tissues in animals will often
be much higher than that delivered to human target tissues. 5 0 Thus,
scientists must rely on a model or theory to estimate the human
response at experimental doses that are often one-thousand-fold below
the lowest tested animal dose as illustrated below. 5 1
Figure 1 depicts a dose-response curve from an exceptionally
thorough (8 dose groups) study. The solid line is a best fit of the eight
data points identified. The three lowest indicate that at these doses, no
increased incidence in tumors was observed in the test animals. The
error bars on the three lowest doses indicate the statistical uncertainty in
the test results since a limited number of animals were tested at each
dose (n = 100). To insure that risk estimates are not underestimated,
the models most frequently used by regulators are based on the upper
bound of the plausible response, rather than the best estimate.
47 Andersen, supra note 25; Ames, supra note 39; Anderson & Alden, supra note
44; Daniel Krewski, D. Murdoch & James R. Withey, Recent Developments in
Carcinogenic Risk Assessment, 57 Health Physics 313 (1989); Lois S. Gold et al.,
Rodent Carcinogens: Setting Priorities, 258 Science 261 (1992) and Food Safety
Council, Quantitative Risk Assessment in Food SafetyAssessment ch. 11 (1980).
48 Ashby & Tennant, supra note 27; Williams & Weisburger, supra note 28 and
Melvin E. Andersen et al., Physiologically-Based Pharmacokinetics and the Risk
Assessment for Methylene Chloride, 87 Toxicol. Appl. Pharm. 185 (1987).
49 Krewski, Murdoch & Withey, supra note 47 and Gold et al., supra note 47.
50 Bois, Zeise & Tozer, supra note 25; Melvin E. Andersen et al., Physiologically-
Based Pharmacokinetic Modeling with Dichloromethane, Its Metabolite, Carbon
Monoxide, and Blood Carboxyhemoglobin in Rats and Humans, 108 Toxicol. Appl.
Pharm. 14 (1991) and Dennis J. Paustenbach et al., A Physiologically-Based
Pharmacokinetic Model for Carbon Tetrachloride, 96 Toxicol. Appl. Pharm. 191
(1988).
51 EPA (1991), supra note 41; Krewski, Murdoch & Withey, supra note 47; Gold
ct al., supra note 47 and Food Safety Council, supra note 47.
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Figure 1






Low-dose extrapolation modeling (sometimes called quantitative
risk assessment [QRA] outside the U.S.) has become the backbone of
dose-response assessments for carcinogens. Because these statistical
models play such a dominant role in the regulatory process, it is useful
to understand some of their characteristics. First, the six most routinely
used models will usually fit the rodent data in the dose region used in
the animal tests.5 2 Second, the different models usually yield very
different results at the doses to which humans are exposed, as
exemplified below by the analysis of DDT (Figure 2) and methylene
chloride. 53
To date, in the U.S. most regulatory approaches for identifying safe
or acceptable levels of exposure to air, water and soil contaminants have
been based on statistical rather than biologically-based models. As
discussed below, the physiologically-based pharmacokinetic (PB-PK)
models are the most scientifically rigorous (and likely most valid)
52 Krewski, Murdoch & Withey, supra note 47 and Food Safety Council, supra
note 47.
53 Paustenbach, supra note 8 and Food Safety Council, supra note 47.
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models for estimating safe levels of human exposure based on animal
data.54
Figure 2












In the not-so-distant future, it can be expected that much greater
weight will be placed on those assessments that attempt to account
quantitatively for biological phenomena. 55 The fit of most dose-
54 Anderson and Andersen et al., supra note 25; Bois, Zeise & Tozer, sup ra note
25; D'Souza & Boxenbaum, supra note 38; Reitz, supra note 38; Andersen et al.,
supra note 48; Andersen et al., supra note 50 and Paustenbach et al., supra note 50.
55 Flamm & Lehman-McKeeman, supra note 26; Connolly et al., supra note 25;
Paustenbach et al., supra note 50; Orville E. Paynter, Gj. Burin & C.A. Gregorio,
Goitrogens and Thyroid Folicular Cell Neoplasia: Evidence for a Threshold Process,8 Reguil. Toxicol. Pharm. 102 (1988); Hon-Wing Leung & Dennis J. Paustenbach,The Acceptance of PB-PK Modelling as a Critical Component of Health Risk
Assessment (Presented, EPA Workshop on PB-PK models, Savannah, GA 1993; Rory
B. Connolly & Melvin E. Andersen, Biologically-Based Pharmacodynamic Models(1991); Dennis J., Paustenbach, et al., Risk Assessment for 2,3,7,8-TCDD Using a
Biologically Based Cancer Model. A Reevaluation of the Kociba et al. Bioassay Using
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response models to data in the observable range is generally similar (left
plot). Yet, due to the differences in the assumptions and equations upon
which the models are based, the risk estimates at low doses (e.g., less
than 0.1mg/kg-day) can vary dramatically between them (right plot).
Finally, as shown in Table 256 the results of commonly-used
models usually vary in a predictable manner because they use different
mathematical equations for predicting the chemical's carcinogenic
potency.
Table 2
Estimates of Lifetime Cancer Risk to Humans from Exposures to Methylene
Chloride Based on Salivary Gland Region Sarcomas in Male Rats Derived
from Four Different Models
(95% Upper Confidence Limit of Additional Risks)
Air Multistage One-Hit Weibull Log-Probit
Concentration Model Model Model Model
(pg/m3)
1 1.8 x 10-7  2.0 x 10-7  4.8 x 10-10  3.5 x 10-3 1
10 1.8 x 10-6  2.0 x 10-6  1.7 x 10-8  1.6 x 10-2 2
100 1.8 x 10-5 2.0 x 10-5 6.1 x 10-6 2.5 x 10-15
1,000 1.8 x 10 4  2.0 x 104 2.0 x 10-5  1.3 x 10-9
10,000 1.8 x 10-5 2.0 x 10-3 6.1 x 10-4 2.4 x 10-1
At most exposures, the one-hit and linearized multi-stage models will
predict the highest risk and the probit model will predict the lowest.57
It is noteworthy that rodent studies now used to predict the
magnitude of human risk were never intended for that purpose.5 8
They were designed to qualitatively identify potential human cancer
hazards, not to quantitatively estimate the human risk at low levels of
exposure. 5 9 As in hazard identification, whenever adherence to strict
1978 and 1990 Histopathology Criteria, 34 J. Toxicol. Environ. Health 11 (1991);
James D. Wilson, Assessment of Low-Exposure from Carcinogens: Implications of
the Knudson-Moolgavkar Two-Critical Mutation Theory in Biologically-Based
Methods in Cancer Risk Assessment 275 (Curtis C. Travis, ed. 1989) and Corley et
al., Yupra note 46.
56 EPA, Health Assessment Document for Dichloromethane (Methylene Chloride)
(Fin. Rep. 1985).
57 Paustenbach, supra note 8.
58 Barnard, Moolenaar & Stevenson, supra note 27; Abelson, supra note 39 and
Barr, supra note 39.
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regulatory guidance requires that dose-response assessments must use a
single mathematical model, the assessment can become so constrained
that valuable biological information (which could dramatically alter the
results) is not fully accounted for.60
We have now learned a good deal about the biology of cancer, and
this information should be considered in the dose-response assessment
whenever possible. For example, we now know that there are at least
three broad classes of mechanisms by which chemicals may produce a
carcinogenic response in rodents: repeated cytotoxicity, promotion and
initiation. 6 1 Some have suggested as many as eight different classes of
mechanisms through which chemicals produce tumors. 6 2 These
distinctions are important since the appropriate model for estimating
the cancer risk for humans exposed to low doses of a cytotoxicant or
promotor should be different than that for an initiator.63 Because at
relatively high doses non-genotoxicants may produce repeated
cytotoxicity, the primary reason for excessive cell turnover, many
scientists expect them to possess a threshold dose below which no
cancer hazard would be present. 64 This is in contrast to genotoxicants
or mutagens that may pose some risk, albeit small, at very low doses.
In general, the scientific underpinnings of the dose-response models
used for assessing carcinogens are based on our understanding of
ionizing radiation and genotoxic chemicals. 6 5 Both types of agents
may well have a linear, or a nearly linear, response in the low-dose
region. However, promoters and cytotoxicants need not have a linear
dose-response curve. Scientific data increasingly suggest that promoters
and other non-genotoxic agents will have a very non-linear dose-
59 Friess, supra note 19.
60 Paustenbach, supra note 17.
61 Andersen, supra note 25; Butterworth, supra note 26; Butterworth & Slaga,
supra note 26 and Williams & Weisburger, supra note 28.
62 Butterworth, supra note 26.
63 Wilson, supra note 55; Daniel Krewski, Charles Brown & Duncan Murdoch,
Determining 'Safe" Levels of Exposure: Safety Factors or Mathematical Models, 4
Fund. App[ Toxicol. 383 (1984) and Kirk Kitchin, Janice Brown & R. Woodrow
Setzer, Dose-Response Relationship in Multistage Carcinogenesis: Promoters, 102
(Supp. 1) Environ. Health Perspect. 255 (1994).
64 Williams & Weisburger, supra note 28.
65 David G. Hoel, Cancer Risk Models for Ionizing Radiation, 76. Environ. Health
Perspect. 121 (1987).
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response relationship at low doses and, as importantly, probably have a
genuine or practical threshold. 6 6 The increased acceptance of this
postulate is evidenced by EPA's position that the linearized multi-stage
model is inappropriate for dioxin,6 7 thyroid type carcinogens, 6 8
nitrilotriacetic acid (NTA),6 9 d-limonene70 and, presumably, similar
non-genotoxic chemicals.
Over the past twenty years, the scientific community has learned at
least six ways to improve the way that regulatory agencies in the U.S.
have predicted the possible human risk at low levels of exposure to
carcinogens (Table 1).
First, we have learned that it is important to identify the best
estimates from the cancer models, as well as the upper and lower
bounds of the risk.7 1 The objective of the bounding techniques is to
attempt to account for the statistical uncertainty in the results of the
animal tests, however, we have rarely presented the degree of potential
conservatism within the bounding procedure. 72 The problem of not
presenting all of the results is that the risk manager will not be fully
aware of the breadth of equally plausible risk estimates. 7 3 For
example, the cancer risk associated with exposure to chloroform in
most U.S. drinking water has been reported to be as high as one in
10,000 using the upper bound risk estimate of the multi-stage
model; 74 however, using the same model, the best or maximum
likelihood estimate (MLE) of the risk is about one in 1M and the lower
bound estimate is virtually zero (about one in ten million). Therefore,
the plausible range of risk is as high as one in 10,000 and as low as zero.
66 Williams & Weisburger, supra note 28.
67 EPA, Health Assessment Document for 2,3,7,8-Tetrachlorodibenzo-p-dioxin
(TCDD) and Related Compounds Vol. I-III (Draft 1994).
68 Paynter, Burin & Gregorio, supra note 55.
69 Anderson & Alden, supra note 44.
70 Flamm & Lehman-McKeeman, supra note 25.
71 Paustenbach, supra note 8.
72 Sielken, supra note 25 and Robert L. Sielken, Useful Tools for Evaluating and
Presenting More Science in Quantitative Cancer Risk Assessments, 9 Tox. Subs. J.
3530(989).
73 Thomas E. McKone & Kenneth T. Bogen, Uncertainties in Health-Risk
Assessment: An Integrated Case Study Based on Tetrachloroethylene in California
Groundwater, 15 Regul. Toxicol. Pharm. 86 (1992).
74 Corley et al., supra note 46.
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When biological factors are considered, such as its weak genotoxicity
and pharmacokinetics, the carcinogenic risk associated with low
concentrations of chloroform in chlorinated drinking water is likely to
be quite small or negligible. 7 5 Yet, as a matter of policy, the risk of one
in 10,000 is most cited by regulators and appears in newspapers.
Second, we have learned not to rely on only one mathematical
model. There are at least six different models that may need to be
considered when estimating the risks at low doses. Each of them can
yield results which are plausible, depending on the mechanism of action
and pharmacokinetics of the chemical, as well as the characteristics of
the dose-response curve. 7 6  With better understanding of
carcinogenesis and the shortcomings of statistical models, regulators
have recently become more willing to consider models that can
quantitatively account for chemical-specific mechanisms of action. 7 7
However, support for encouraging flexibility in the risk-estimation
process has been criticized on the grounds that our knowledge about
carcinogenesis is insufficient to regulate in other than a very conservative
manner. 7 8 The application of Monte Carlo techniques to dose-
response assessment and the polling of experts should help resolve some
of these philosophical differences in how to establish regulatory goals.
Third, we need to give greater weight to epidemiology studies. It is
usually claimed that these studies are almost never as statistically robust
as the animal studies and, therefore, are not very useful.7 9 Yet, total
acceptance of this assertion is inappropriate because epidemiological
studies can, at least, establish the degree of confidence that should be
placed in the results of low-dose extrapolation models. 80 Often, even
75 Id.
76 Sielken, supra note 25; Starr & Buck, supra note 25 and Anderson & Alden,
supra note 44.
77 Andersen et al., supra note 48; Corley et al., supra note 46 and EPA, supra
note 67.
78 Silbergeld, supra note 18; Fredrica Perera, The Genotoxic/-Epigenetic
Distinction: Relevance to Cancer Policy, 34 Environ. Res. 175 (1984) and Fredrica
Perera & Pat Boffetta, Perspectives on Comparing Risks of Environmental
Carcinogens, 80 J. Natl. Cancer Inst. 1282 (1988).
79 Ellen K. Silbergeld, Epidemiology versus Risk Assessment: Resolving Some Old
Controversies, 8 RiskAnal. 555 (1988).
80 Goodman & Wilson, supra note 25; Kenny S. Crump, Correlation of
Carcinogenic Potency in Animals and Humans, 5 Cell Biol. Toxicol. 393 (1989);
MaxwelI Layard & Abe Silvers, Epidemiology in Environmental Risk Assessment, in
Paustenbach: Retrospective on U.S. Health Risk Assessment 303
less-than-perfect epidemiology, coupled with retrospective exposure
assessments, can yield much more defensible estimates of likely human
health hazards than statistical models based on animal studies. Recent
work evaluating benzene furnishes an example.
81
Fourth, we should quantitatively scale up data from rodents to
predict the human response. For example, when evaluating most
toxicologic effects, statisticians and biologists have generally assumed
that at a given dose (mg/kg-day) the rodent response to a chemical will
be nearly identical to the human response. This approach is usually
reasonably accurate for noncarcinogenic effects. In contrast, for
carcinogens, several factors need to be considered when trying to
predict how humans will respond compared to rodents. First, the
biologic half-life between rodents and humans can be expected to be
different for virtually all chemicals. Often, for a given chemical, these
differences will vary in a predictable manner based simply on the body
weight to surface area ratio and/or the life span. 82 This may be valid
for those chemical carcinogens which require metabolic activation, but
may not be very accurate for those carcinogens that do not.
Consequently, for regulatory purposes, surface area corrections have
been used in an attempt to adjust for the pharmacokinetic differences
between rodents and humans. Recent work suggests that body weight
The RiskAssessment of Environmental and Human Health Hazards: A Text Book of
Case Studies 157 (D. J. Paustenbach, ed. 1989) and Dennis J. Paustenbach & William
J. Butler, Discussion of John D. Graham, "Epidemiology and Risk Assessment: They
Aren't Antonyms!" at Federal Focus Conference: The Role of Epidemiology in
Regulatory Risk, Annandale VA, Oct.. 13-14, 1994.
81 Dennis J. Paustenbach et al., Re-Evaluation of Benzene Exposure for the Pliofilm
Workers (1939-1976), 36 J. Toxicol. Environ. Health. 177 (1992); Mary B. Paxton et
al., Leukemia Risk Associated with Benzene Exposure in the Pliofilm Cohort: L
Mortality Update and Exposure Distribution, 14 Risk Anal. 147 (1994); Mary B.
Paxton et al., Leukemia Risk Associated with Benzene Exposure in the Pliofilm
Cohort: I. Risk Estimates, 14 RiskAnal. 155 (1994) and Kenny S. Crump, Risk of
Benzene-Induced Leukemia: A Sensitivity Analysis of the Pliofilm Cohort with
Additional Follow-up and New Exposure Estimates, 42 J. Toxicol. Environ. Health.
219 (1994).
82 EPA, A Cross-Species Scaling Factor for Carcinogen Risk Assessment Based on
Equivalence of Mg/Kg3/4/Day (Draft Report), 57 Fed. Reg. 24,152 (1992); Curtis
C. Travis & Robin K. White, Interspecies Scaling of Toxicity Data, 8 RiskAnal. 119
(1988); D. A. Freedman & H. Zeisel, From Mouse to Man: The Quantitative
Assessment of Cancer Risk, 3 Statis. Sci. 3 (1988) and Richard H. Reitz,
Quantitating the Production of Biologically Reactive Intermediates in Target Tissues:
Example, Dichloromethane in Advances in Experimental Biology and Medicine, Vol.
283, Biological Reactive Intermediates IV, (C. M. Witmer et al., eds. 1991).
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to the 2/3 power is the most valid scale-up factor if no compelling
information to the contrary is available. 83
Table 3
PB-PK Models Have Been Developed for at Least 40










































The most promising method for predicting the human response
from rodent data is the physiologically-based pharmacokinetic model
(PB-PK).84 These quantitatively account for the various differences
between the test species and humans by considering body weight,
metabolic capacity and products, respiration rate, blood flow, fat
content and several other parameters.
Figure 385 depicts a physiologically-based pharmacokinetic (PB-
PK) model for inhalation exposure to 1 4 C-carbon tetrachloride.8 6
Such models allow scientists to predict how humans will respond to a
83 EPA, supra; Travis & White, supra and Allen, Crump & Shipp, supra note 27.
84 Andersen, supra note 25; Andersen et al., supra notes 25, 48 and 50;
Paustenbach & Butler, supra note 81 and Hon-Wing Leung, Development and
Utilization of Physiologically Based Pharmacokinetic Models for Toxicological
Applications, 32 J. Toxicol. Environ. Health 247 (1991).
85 Leung, supra.
86 Dennis J. Paustenbach, A Physiologically-Based Description of the Inhalation
Pharmacokinetics of Carbon Tetrachloride, 96 Toxicol. Appl. Pharm. 191 (1986).
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chemical based on data collected in rodents. Basically, the movement
and transformation of the test chemical within the rodent is described
by mathematical equations. The same is done for the human. If the
rodent data tracks a chemical's behavior in humans, one can be
confident that the model can quantitatively predict the human response
at several different doses.
Figure 3
A PB-PK Model for Inhalation Exposure to 14C-C14
This methodology has only been used by toxicologists since about
1984 but became widely accepted by 1991. Although the results of PB-
PK models often rely on some frequently untestable assumptions such
as the delivered dose of an unstable metabolite to a target organ, it
represents one of the most important advances in toxicology and health
risk assessment of the past 50 years. The variability in predicting the
results in humans based exclusively on the animal data can be
significant and some of these have been evaluated. 87 To date, PB-PK
87 Christopher J. Portier & M. L. Kaplan, The Variability of Safe Dose Estimates
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models have been developed and validated for carbon tetrachloride,
styrene, methylene chloride, chloroform, trichloroethane, dioxane,
tetrachlorodibenzo-p-furan, tetrachlorodibenzo-p-dioxin (TCDD),
benzene, trichloroethylene, vinyl chloride, and others (Table 2). The
benefits of this approach have been so impressive that two major
symposia have been held to encourage its use; one by the National
Academy of Science (NAS) 88 and the other by the EPA in 1993.89
The fifth, and possibly most important, lesson we have learned is
that low-dose models are useful for ranking classes of carcinogens
objectively, but they should not be expected to precisely predict the
cancer risk because they cannot account for biological information such
as the mechanism of action, types of tumor, differences among species,
metabolism and genotoxicity. Perhaps the most promising approach to
incorporating biologic factors into cancer risk estimates is the use of
biologically-based models such as the one by Moolgavkar-Knudson-
Venzon (MKV). 90 This model accounts for the number of mutations
required for malignancy and the role of target cell birth and death
processes associated with these mutations. A key element is a
quantitative description of how the carcinogen affects the cellular birth,
death and mutation rates. Unfortunately, because most of the
information needed to perform these analyses is not yet available, and
may not be measurable, it holds limited promise in the near future.
Sixth, experience has shown that EPA-recommended cancer models
often do not respond to the characteristics of the dose-response curve.
As discussed by Sielken, 9 1 it does not seem appropriate to base
important regulatory decisions on the results of models which are
minimally "responsive" to the very costly information collected in
When Using Complicated Models of the Carcinogenic Process: A Case Study -
Methylene Chloride, 13 Fund. Appl. Tox. 533 (1989); Harvey J. Clewell, Tze-San
Lee & R.L. Carpenter, Sensitivity of Physiologically-Based Pharmacokinetics Models
to Variation in Model Parameters: Methylene Chloride, 14 RiskAnal. 533 (1994)
and Daniel Krewski, Duncan J. Murdock & James R. Withey, The Application of
Pharmacokinetic Data in Carcinogenic Risk Assessment, Pharmacokinetics in Risk
Assessment (1987), Vol. VIII in the series Drinking Water and Health.
88 Krewski, supra.
89 Leung & Paustenbach, supra note 55.
90 Moolgavkar, Dewanji & Venzon, supra note 26 and Suresh H. Moolgavkar &
Alfred G. Knudson, Mutation and Cancer: A Model for Human Carcinogenesis, 66
J. Nail. Cancer Inst. 1037 (1981).
91 Siclken, supra note 25 and Sielken, supra note 72.
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standard lifetime rodent studies. Another way to look at this is to
understand the fragility or sturdiness of these models not only when
interpreting bioassay data, but also when selecting the dosing regimen
to be used in future bioassays. If one conducts only one statistical test
to select the form of the model, this limits the ability to learn as much
as possible from rodent data. A way to avoid this problem is to conduct
simulations of the model's responsiveness to alternative, but similar,
data sets to ensure that the extrapolation is reasonable. 92 As shown by
Reith and Starr, 93 the potential range of tumor incidences that may be
analyzed with the multistage model are restricted by the experimental
design (specifically, by numbers of doses and animals) of the bioassay;
this in turn limits the possible values of carcinogenic potency that can
arise. This needs to be considered when selecting the doses to be used
in biassays.
Exposure Assessment
Of the four portions of a risk assessment, exposure assessment has
made the biggest improvement in quality over the history of health risk
assessment. 94 In general, exposure assessment should contain less
uncertainty than other steps in risk assessment. Admittedly, a large
number of factors need to be considered when estimating exposure,
and it is a complicated procedure to understand the transport and
distribution of a chemical after release into the environment. 9 5
Nonetheless, available data indicate that scientists can do an adequate
job of quantifying the concentration of chemicals in various media and
resulting uptake by exposed persons if they account for all factors that
92 Sielken, supra note 25.
93 James P. Reith & Thomas B. Starr, Experimental Design Constraints on
Carcinogenic Potency Estimates, 27 J. Toxicol. Environ. Health 287 (1989) and
James P. Reith & Thomas B. Starr, Chronic Bioassays: Relevance to Quantitative
Risk Assessment of Carcinogens, 10 Regul. Toxicol. Pharm. 160 (1989).
94 Paustenbach supra note 1, Finley & Paustenbach, supra note 17; Finley et al.,
supra note 17 and Brent L. Finley, Paul Scott & Dennis J. Paustenbach, Evaluating
the Adequacy of Maximum Contaminant Levels as Health Prospective Cleanup
Goals: An Analysis Based on Monte Carlo Techniques, 18 Regul. Toxicol. Pharm.
438 (1993).
95 George F. Fries & Dennis J. Paustenbach, Evaluation of Potential Transmission
of 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Contaminated Incinerator Emissions to
Humans via Foods, 29 Toxicol. Environ. Health 1 (1990) and Thomas E. McKone,
Human Exposure to Chemicals from Multiple Media and Through Multiple
Pathways: Research Overview and Comments, 11 RiskAnal. 5 (1991).
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should be considered. 96 For some chemicals, the actual uptake by
exposed persons need not be estimated; they can often be measured
directly in body fluids, excrement or hair.97
The primary routes of exposure to chemicals in the environment are
inhalation of dusts and vapors, dermal contact with contaminated soils
or dusts, and ingestion of contaminated foods, water or soil. 98 Initial
efforts to quantitatively estimate the uptake of environmental
contaminants by humans were first conducted by scientists in the field
of radiological health99 and their work can be a source of valuable
information when conducting assessments of chemical contaminants.
Numerous methodologies for estimating the human uptake of
contaminants have been proposed and refined in recent years. 10 0
We have learned at least eleven rather significant lessons about
conducting exposure assessments that can immediately be adopted
elsewhere. These could potentially save other nations hundreds of
millions of dollars and thousands of person-years of work (Table 1).
First, U.S. experience has shown that in attempts to be prudent, we
have overemphasized the "maximally exposed individual" (MEI). 1° 1
96 T. Lavy, J. Shepard & D. Bouchard, Field Worker Exposure and Helicopter
Spray Pattern of2,4,5-T, 24 Bull. Environ. Contain. Toxicol. 90 (1980) and T. Lavy
et al., (2,4-Dichlorophenoxy)Acetic Acid Exposure Received By Aerial Application
Crews During Forest Spray Operations, 30 J. Agric. Food Chem. 375 (1982).
97 Adrian Lynch, Methods in Biological Monitoring (1987).
98 Fries & Paustenbach, supra note 95; McKone, supra note 95; Renate D.
Kimbrough et al., Health Implications of 2,3,7,8-etrachlorodibenzo-p-dioxin
(TCDD) Contamination of Residential Soil, 14 J. Toxicol. Environ. Health 47
(1984); Alan E. Eschenroeder et al., Health Risk Analysis of Human Exposures to
Soil Amended With Sewage Sludge Contaminated With Polychlorinated
Dibenzodioxins and Dibenzofurans, 28 Vet. Hum. Toxicol. 435 (1986) and Dennis
J. Paustenbach et al., An Assessment and Quantitative Uncertainty Analysis of the
Health Risks to Workers Exposed to Chromium Contaminated Soils, 7 Toxicol.
Ind. Health 159 (1991).
99 E. M Romney et al., Contamination of Plant Foliage with Radioactive Nuclides,
14 Ann. Rev. Plant Physiol. 271 (1963); W. E. Martin, Loss of Sr-90, Sr-89 and I-
131 from Fallout of Contaminated Plants, 4 Radiat. Bot. 275 (1964); R. S. Russell,
Entry of Radioactive Materials into Plants, in Radioactivity and Human Diet, Ch. 5
(R.S. Russell, ed. 1966); C. F. Baes III et al., A Review and Analysis of Parameters for
Assessing Transport of Environmental Released Radionuclides Through Agriculture
(1984) and EPA, Assessing Exposure to Dioxin-like Compounds (1993).
100 Finley et al., supra note 17; Paustenbach et al., supra note 98; Thomas E.
McKone & Jeffrey I. Daniels, Estimating Human Exposure Through Multiple
Pathways fom Air, Water, and Soil, 13 Reg. Toxicol. Pharm. 36 (1991) and
California Environmental Protection Agency, The Caltox Program (1994).
101 Nichols & Zeckhauser, supra note 17; Daniel Maxim, Problems Associated
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Often, the results of these analyses were misinterpreted by the public
and/or misrepresented by some scientists or lawyers. For example,
some assessments addressed only risks to the MEL. Yet, that the risk
may affect only the 99.5th or 99.9th percentile of all exposed
populations was rarely stated. Current EPA exposure guidelines and
NAS guidance acknowledge this deficiency and note that a worst-case
or MEI analysis should be used only to decide if an exposure is
insignificant and should not be used to characterize the actual or
plausible human risks. In short, most MEI analyses should only be used
in screening assessments, although some have noted that so-called
"reasonable" person assessments often don't present the full picture. 102
Second, as we have learned to characterize accurately the risks of
exposure for about 95% of the population, more emphasis has been
placed on evaluating various special groups (e.g., Eskimos, subsistence
fisherman, dairy farmers), who can be exposed to particularly high
doses (the 95%-99.9% group). Although the risk for these populations
needs to be understood, the typical levels of exposure for the majority
of exposed individuals should be the initial focus of most risk
assessments. For example, if a regulatory agency bases its decision on
the results of an assessment of persons who eat about 100g of freshwater
fish every day (99th percentile), yet the average American eats only 18 g
of fish per day (lifetime average), the analysis should reflect the fact
that 99 of 100 persons are not represented by the corresponding risk
estimate. To help minimize the potential for misunderstanding, it is
important to describe the number of exposed persons at each
anticipated dose level, along with the most likely and upper estimates
of exposure and the associated plausible risk. 103 With this information,
risk managers can decide whether large or small sums of money are
warranted to reduce the health hazard.10 4
with the Use of Conservative Assumptions in Exposure & Risk Analysis, in The Risk
Assessment of Environmental and Human Health Health Hazards: A Textbook of
Case Studies 525 (D. J. Paustenbach, ed. 1989); Finley & Paustenbach, supra note
17; Hawkins, supra note 17; Copeland et al., supra note 17 and Barnard Goldstein,
The Problem with the Margin of Safety: Toward the Concept of Protection, 10 Risk
Anal. 7 (1990).
102 Adam M. Finkel, Is Risk Assessment Really Too Conservative? Revising the
Revisionists, 14 Colum. J. Environ. L. 427 (1989).
103 Paustenbach, supra note 17 and Betsy Ruffle et al., Lognormal Distributions for
Fish Consumption by the General U.S. Population, 14 RiskAnal. 395 (1994).
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Third, don't allow the repeated use of conservative assumptions to
dictate assessment results. In recent years, several investigators have
discussed this issue and have demonstrated its importance. 10 5 The
problem can be illustrated by one assessment of the dioxin hazard
posed by municipal waste incinerators. Before deciding to issue a
permit, the EPA conducted a screening level assessment, evaluating the
theoretical cancer risk for a child who lived within a short distance (0.8
KM) from the hypothetical incinerator. They assumed that a child
could eat as much as about one small spoonful of dirt each day, that his
house was down-wind of the stack, that he ate fish from a pond near
the incinerator, that his fish consumption was at the 95th percentile
level, that he drank contaminated water from the pond, that he ate
food grown primarily from the family garden, and that he drank milk
from a cow which grazed on forage at the farm. Not surprisingly, it was
predicted that siting the incinerator could plausibility increase the
child's lifetime cancer risk (if he lived there for 70 years) by one in 100;
but he could hardly be portrayed as a typical person living near a
municipal incinerator. Regrettably, the associated upper-estimate of the
risk was the only one reported by the press. Certainly, it would have
been more appropriate to have studied and presented the number of
persons likely to be exposed to this amount of contaminant, as well as
the level of exposure for the typical person living within ten miles of the
facility. It may also have been useful to note that few farms are located
near most incinerators since operators try to minimize transportation
costs from urban areas.
Fourth, in exposure assessment the problems associated with the
repeated use of overly conservative assumptions and the need to
properly account for small (but highly exposed) populations can now be
overcome with Monte Carlo techniques. 106 The probabilistic or Monte
104 Breyer, supra note 19; Graham, supra note 22 and Richard Wilson & W. Clark,
Risk Assessment and Risk Management: Their Separation Should not Mean Divorce
in RiskAnalysis 187 (C. Zervos, ed. 1991).
105 Nichols & Zeckhauser, supra note 17; Maxim, supra note 101; Finley &
Paustenbach, supra note 17; Hawkins, supra note 17, Copeland et al., supra note
17; Burmaster & von Stackelberg, supra note 25 and McKone & Bogen, supra note
73.
106 Finley et al., supra note 17; Copeland et al. (1993 and 1994), supra note 17;
Moolgavkar, Dewanji & Venzon, supra note 25 and Kimberly M. Thompson, David
E. Burmaster & Edmund A.C. Crouch, Monte Carlo Techniques for Quantitative
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Carlo technique addresses the main deficiencies of the point estimate
approach because it imparts a great deal more information to the risk
manager.
Figure 4 illustrates how a Monte Carlo analysis is applied to
understand the distribution of time needed to go shopping based on
the three activities involved in shopping. Time spent shopping each
month (minutes) is estimated by the product of two parameters: the
number of trips per month and the total time spent in the store
(minutes). Total time spent in the store is the sum of time spent
shopping and time spent in line. Using Monte Carlo techniques, a
distribution of likely values is associated with each of these parameters.
These distributions are dependent upon the detail of information
available to characterize each parameter. For example, the distribution
compares all of the information such as those days when the line at the
check-out counter is short, as well as those when it's long. It is
noteworthy that each parameter has a different distribution: log-
normal, gaussian, and square. Total time spent shopping is then
calculated repeatedly by combining parameter values that are randomly
selected from these distributions. The result is a distribution of likely
time spent shopping each month. Using this technique, information
concerning each parameter is carried along to the final estimate.
Instead of presenting a single point estimate of risk, probabilistic
analyses characterize a range of potential risks and their likelihood of
occurrence. In addition, those factors which most affect the results can
be easily identified. For example, in a probabilistic analysis, one can
present the risk manager with the following type of statement:
The plausible increased cancer risks for the 50th, 95th, and
99th percentiles of the exposed population are 1 x 10-8, 5 x
10-7 and 1 x 10-6, respectively. However, if there was to be
a fishing ban on catfish and other bottom feeders, the risks
for the 50th, 95th, and 99th percentile groups would drop
by 100-fold.
Uncertainty Analysis in Public Health Risk Assessments, 12 RiskAnal. 53 (1992).
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Fifth, risk managers and the public want to know the statistical
confidence in risk estimates. Sensitivity analyses can yield important
information about critical exposure variables; 107 e.g., we can now state:
Our understanding of the concentration of DDT in the
edible portion of smallmouth bass, is based on high quality,
reliable data; therefore, our confidence in the risk estimates
is high. Our analysis indicates a 95% level of confidence
that 90% of the increased cancer risk could be eliminated
by a ban on catching carp or catfish in the river and that
little additional risk reduction would be achieved if bass and
trout fishing were also banned.
This type of characterization provides the kind of information risk
managers need to make informed decisions regarding the necessary
magnitude of response, the cost/benefit of particular decisions, and
whether a range of risk-reduction alternatives should be considered.
We have also refined our approach to conducting statistical analyses
of environmental data (lesson six). For example, we now see the
importance of accounting for the log-normal and truncated
distributions. As has been shown repeatedly, most environmental and
occupational data are log-normally distributed rather than conform to a
gaussian distribution, 108 but few environmental scientists were aware of
the significance until recently. As noted in the recently proposed EPA
guidelines for exposure assessment, inappropriate statistical analysis of
environmental data is one of the most easily corrected of the common
errors in exposure analysis. 109
Seventh, we have improved techniques for statistically handling
samples having no detectable amount of contaminants.1 10 Frequently,
agencies have used the limit of detection (LOD) in exposure
107 Steve M. Rappaport & James Selvin, A Method for Evaluating the Mean
Exposure from a Log-Normal Distribution, 48 Am. Ind. Hyg. Assoc. J. 374 (1987);
Richard 0. Gilbert, Statistical Methods for Environmental Pollution Monitoring
(1987); Curtis C. Travis, Miriam L. Land & Holly Hattemer-Frey, Estimating the
Mean of Data Sets with Nondetectable Values, 24 Environ. Sci. Technol. 961 (1990)
and Charles N. Haas & Peter A. Scheff, Estimation of Averages in Truncated
Samples, 24 Environ. Sci. Technol. 912 (1990).
108 See references, supra and T. B. Parkin et al., Evaluation of Statistical
Estimation Methods for Lognormally Distributed Variables, 52 Soil Sci. J. 323
(1988).
109 EPA, Guidelines for Exposure Assessment., 57 Fed. Reg. 22888 (1992).
110 Travis, Land & Hattemer-Frey, supra note 107.
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calculations on the premise that the contaminant might be present at
that level. Many agencies have suggested that 50% of the LOD should
be used to calculate the plausible degree of human exposure when no
detectable amount is identified; others have suggested that the LOD
divided by the square root of two, and other much more complex
approaches have been recommended. In short, when such approaches
are used on a site that may only be 2-10% contaminated (based on
surface area) the impact of a few samples on the calculated average level
of contamination will be much higher than what is likely to be present
across the site unless proper statistical methods are applied. Several
approaches have been suggested to help avoid this problem. 11 1
Eighth, we need to account for the environmental fate of chemicals.
Many factors such as degradation by sunlight, soil and water microbes,
and evaporation can dramatically influence the degree of human
exposure. Yet, many assessments have frequently assumed
concentrations measured today will exist and remain constant for
30-50 years. 1 12 For instance, the public health hazard posed by the
potential release of dioxin vapors from incinerators was recently
evaluated. After it was alleged that the vapors posed a serious health
hazard to surrounding residents, a risk assessment was conducted. Yet,
the environmental half-life of dioxin (as a vapor) proved to be critical
because it has a half-life of only 90 minutes. In contrast, TCDD in
deep soil, fly-ash or sediment may have an environmental half-life of
50-500 years. What had been portrayed as a potentially serious health
hazard was shown to be insignificant, given its photolytic half-life.1 13
Ninth, we have recognized the need to validate exposure
assumptions or model estimates by using field measurements. Although
past sampling and analytical procedures were inadequate to measure the
low concentrations of toxicants found in the environment, better ones
are now available. As field measurement techniques are further refined,
111 N. Cressie, Statistics for Spatial Data (Revised 1993) and J. D. Istok, J. D.
Smyth, & A. L. Flint, Multivariate Geostatistical Analysis of Groundwater
Contamination: A Case History, 31 Groundwater 63 (1993).
112 Maxim, supra note 101; Dennis J. Paustenbach et al., The Potential Inhalation
Hazard Posed by Dioxin-Contaminated Soil, 41 J. Air. Waste Mgt. Assn. 1334
(1991) and Edward J. Calabrese & Paul T. Kostecki, Risk Assessment and
Environmental Fate Methodologies (1992).
113 Paustenbach et al., supra.
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less reliance should be placed on mathematical models for predicting
chemical distributions in the environment, and more confidence should
be placed on environmental samples. 1
14
Tenth, and perhaps the most significant advance in exposure
assessment of airborne contaminants, is recognition of the need to
account for indirect exposure pathways. For example, the uptake of a
contaminant in water by direct ingestion is obvious, but uptake of the
same contaminant from watering garden vegetables or inhaling volatiles
while showering have not always been evaluated. 115 When regulating
airborne nonvolatiles, the most important indirect route of exposure,
not considered before 1986, may be ingestion of particulates deposited
on plants subsequently eaten by grazing animals. 1 16 The ingestion of
the meat and milk from these animals can produce, depending on the
chemical and conditions, risks 50-200 fold greater than that from
inhalation. 1 17 Methods for estimating uptake through virtually all
indirect routes have been developed and continue to be refined. 118
Finally, whenever possible one should use biological monitoring to
confirm predicted human exposures. Over the past five to ten years,
analytical chemists can increasingly detect very small quantities of
dozens of chemicals in the blood, urine, hair, feces, breath and fat of
exposed persons. Measuring parts per trillion and part per quadrillion is
now possible. For many chemicals, this represents a direct indicator of
recent exposure, and in some cases like PCBs and dioxins, chronic
exposure. For example, the uptake of dioxin by Vietnam veterans
exposed to 2,4,5-T was recently evaluated by analyzing the amount of
dioxin in their blood. This study, conducted almost fifteen to twenty
years after the last day of service in Vietnam, allowed epidemiologists
114 Calabrese & Kostecki, supra note 112.
115 James Byard, Hazard Assessment of 1,1,1-Trichloroethane in Groundwater, in
The RiskAssessment of Environmental and Human Health Hazards: A Textbook of
Case Studies 331 (D. J. Paustenbach, ed. 1989) and Wan C. Jo, Clifford P. Weisel &
Paul J. Lioy, Routes of Chloroform Exposure and Body Burden from Showering
with Chlorinated Water, 10 RiskAnal. 575 (1990).
116 Fries & Paustenbach, supra note 95.
117 Id. and James B. Stevens & Elizabeth N. Gerbec, Dioxin in the Agricultural
Food Chain, 8 RiskAnal. 329 (1988).
118 McKone & Daniels, supra note 100; Copeland et al (1994), supra note 17; Fries
& Paustenbach, supra note 95; and California Air Pollution Control Offices
Association, Handbook (1990).
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to conclude that the vast majority of veterans had only a modest degree
of exposure to a chemical alleged to produce numerous adverse health
effects in field soldiers. 119
Risk Characterization
Characterizing risk has consistently been the weakest part of risk
assessments because it requires assessors to draw on many aspects of
science and regulatory policy to describe specific human health
hazards. 12 0 Thorough characterization of chemicals should discuss
background environmental and human tissue concentrations,
pharmacokinetic differences between test animals and humans, the
impact of using a PB-PK or biologically-based model, the effect of
selecting specific exposure parameters, uncertainty and statistical
sensitivity analyses and other factors
A first-rate risk characterization now offers numerous opportunities
to describe the "big picture." It has become generally accepted in the
U.S. that theoretical increases in cancer risk of one in 1M or even one in
10,000 from exposure to an environmental contaminant should not be
depicted as a serious health risk. 12 1 Risks predicted in most assessments
are usually the upper, not the best, estimate of risk. It has been
recommended that every assessment should state that risk estimates
represent an upper bound of plausible risk (when appropriate), are
unlikely to underestimate risk, and that actual risk may be much lower,
even zero.122 In short, it is important to communicate that conservative
procedures and models are likely to overestimate human risk. 12 3 Yet, if
risks may be underestimated, this, too, needs to be stated. 124
119 Larry Needham, Serum 2,3,7,8-Tetrachlorodibenzo-p-dioxin Levels in U.S.
Army Vietnam-Era Veterans: CDC Veterans Heath Studies, 260 J. AMA 1249
(1988) and William H. Wolfe et al., Determinants of TCDD Half-Life in Veterans
of Operation 'Ranch Hand, "41 J. Toxicol. Env. Health 481 (1994).
120 Paustenbach, supra note 17.
121 Curtis C. Travis et al., Cancer Risk Management: A Review of 132 Federal
Regulatory Decisions to Files, 21 Environ. Sci. Technol. 415 (1987) and Curtis C.
Travis & Holly A. Hattemer-Frey, Determining Acceptable Levels of Risk, 22
Environ. Sci. Technol. 873 (1988).
122 'EPA, Cincinatti Office of Environmental Assessment, Health Assessment
Document for Trichloroethylene (1982).
123 Thomas E. McKone & Kenneth T. Bogen, Predicting the Uncertainties in Risk
Assessment, 25 Environ. Sci. Technol. 16 (1991) and Copeland et al. (1994), supra
note 17.
124 Finkel, supra note 102; Wilson & Clark, supra note 104; David Farrar et al.,
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Second, we have learned to account for background contaminant
levels. 125 In assessments of the 1970's and 1980's, risks from natural
and/or background levels likely to have influenced risk managers were
often overlooked. For example, in a preliminary decision regarding the
necessary level of clean-up at a Superfund site in a rural community, the
state agency suggested that soil levels of a cyclodiene be reduced to 10
ppm - to keep the theoretical cancer risk below one in 1M. However,
the administrator decided not to require remediation when it was
recognized that the background levels of some cyclodienes in many
areas in the U.S. exceed 50 ppm and that no adverse health effects had
been observed or suspected.
126
Third, and perhaps most interesting, we learned during early years
of the environmental movement that the hazard may not always be as it
appears. For example, at several sites where large sums of money were
used to remove lead- or PCB-contaminated soil, there was no decrease
in the blood levels of these contaminants in local children or adults. 127
How could this be? As we have since learned, a primary route of uptake
is through the dust in the home which has been transferred from the
soil via tracking or deposition of airborne particulate. Thus, cleaning
homes is often more effective in reducing the health risks than
removing the contaminated soil from the community; and certainly
one must accompany the other. In many locations, this type of rather
simple but practical solution may be the only financially plausible one
for dealing with soil contaminated by persistent chemicals. Thus only
paving over contaminated soil (like mine waste that covers hundreds of
acres) and then conducting a thorough cleaning of the homes may be a
reasonable, although temporary, approach to bringing about a rapid
decrease in the health risk.
Evaluation of Uncertainty in Input Parameters to Pharmacokinetic Models and the
Resulting Uncertainty in Output, 49 Toxicol. Lett. 371 (1989); Adam M. Finkel, A
Quantitative Estimate of the Extent of Human Susceptibility to Cancer and Its
Implications for Risk Management (1994) and Barry Commoner, The Hazards of
Risk Assessment, 14 Colum. J. Environ. L 365 (1990).
125 Brent L. Finley & Dennis J. Paustenbach, Using Risk Assessment to Design
Cost-Effective Remedial Investigation: A Case Study, 5 Econ. 57 (1990) and R. L
Bornshein et al., Lead in Soil: Issues and Guidelines (B.E. Davies and B.G. Wixson,
eds. 1988).
126 Finley & Paustenbach, supra.
127 Bornschein et al., supra note 125.
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Fourth, we have learned that the significance of model-estimated
cancer risks needs to be communicated thoroughly and
understandably. For example, the goal of some standards, such as the
maximum contaminant levels (MCLs) for drinking water, is to keep the
maximum plausible cancer risk between one in 100,000 and one in 1M.
However, it might be useful to note that about 30% of all Americans
will develop cancer and about 25% will eventually die from it.
Accordingly, a I x 10-6 risk is equivalent to ensuring that the lifetime
cancer risk for persons exposed to this level of contamination will be no
greater than 250,001 in 1M (25.0001%), rather than the background
rate of 250,000 in 1M (25%). If society demands this standard of care,
that is its choice. However, both society and its risk managers should
understand the relative magnitude of various risks before deciding to
spend money on one hazard over another. As recently noted by
Gough, 12 8 even if the EPA were to regulate all carcinogens in air, soil
and water at levels generally considered insignificant, the decrease in
cancer incidence in the U.S. would probably be only about 0.25% to
1.3% of the annual cancer mortality.
Fifth, since the late 1980's, risk characterizations have been found
much more useful if they contain cost/benefit analyses. In general, the
public and its elected officials want to know, for each dollar spent, how
much risks are apt to be reduced for various portions of the population.
Most risk scholars and managers believe that such analyses are the
primary justification for performing risk assessments. 12 9 For these
applications the use of Monte Carlo techniques has been invaluable.
Sixth, we now recognize that the hallmark of a good risk
characterization is a discussion of the uncertainties in the risk estimates.
Since 1990, many improvements have been made concerning how to
conduct quantitative, rather than qualitative, uncertainty analyses and
how to present them. 13 0 The key element of these analyses is a
statistical evaluation of each of the various parameters and the
128 Gough, supra note 22.
129 Wildavsky, supra note 19; Dwight D. Briggs & Lester B. Lave, Regulating
Coke Oven Emissions, in Quantitative Risk Assessment in Regulation ch. 5 (Lester B.
Lave, ed. 1982).
130 Finley et al., supra note 17; McKone & Bogen, supra note 73 and" M. Granger
Morgan & Max Henrion, Uncertainty. A Guide to Dealing with Uncertainty in
Quantitative Risk and PolicyAnalysis (1990).
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implication with respect to the risk estimate for various segments of the
population. Although at first blush this may sound like a scientific
nuance, the public and the courts now insist on understanding the level
of confidence in risk predictions.
A key trait of a high-quality risk characterization is the accurate and
unbiased discussion of our confidence in the risk estimates. Often,
regulatory agencies and the press have erroneously stated or implied
that the results of low-dose models actually predict the increased cancer
risk for exposed individuals. As noted previously, because statistical
models cannot account for all biological mechanisms (including repair),
they cannot accurately predict the actual cancer risk. As discussed by
Dr. Frank Young, a former FDA Commissioner, risk estimates should
not be portrayed as anything more than relative indicators of risk.
13 1
He noted, for example, that when the FDA uses the risk level of one in
1M, it is confident that the risk to humans is virtually nonexistent,
rather than one in 1M exposed persons is likely to develop cancer. 132 As
noted by Finkel, risk scholars and policy makers have rarely used
model-derived estimates to predict the incidence of cancer but rather
only as a risk-ranking tool.
Although the U.S. may well have spent a large fraction of its
environmental monies over the past twenty years attacking problems
which were of modest importance, and many of the decisions were
influenced by the poor quality of risk characterizations, this level of
regulatory activity clearly raised public awareness. Much of their
concern however, focussed on the possibility that exposure to industrial
chemicals might increase the cancer risk and the public had been
convinced by many scientists that there was "no safe level of exposure"
to a carcinogen. To most toxicologists, the public's anxiety about
exposure to very low concentrations (e.g., doses) of carcinogens was
generally greater than it needed to be, nonetheless these concerns fueled
the fire to pass more regulations. Fortunately, a significant amount of
work has been invested by researchers in an attempt to improve the way
we characterize risk so that decision making is likely to be more
reasoned in the future. One issue over which we have argued was how to
define the word "safe" when talking about exposure to carcinogens.
131 Young, supra note 9.
132 Id.
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A very recent paper appears to do a good job at describing what
most people would agree was a "safe" level of exposure or what would
constitute "acceptable risk." The authors suggest that if dose is
portrayed in units of molecules of exposure, then it would be easier to
identify at what dose a cancer risk can be considered "safe." The
authors discuss the potent animal carcinogen dioxin (TCDD) in their
paper: 133
The probability of developing cancer with exposure to
one molecule of 2,3,7,8-TCDD a day over a lifetime is
calculated by the upper bound EPA approach to be less than
2 x 10-15. Given the astronomical numbers of cells and
molecules that exist in the human body and the myriad of
factors that could prevent a single interaction of a
carcinogen-molecule with a strand of DNA from ultimately
creating a tumor, it is not surprising that we should calculate
an extremely small risk for such an infinitesimally small level
of exposure.
To empower individuals to decide if a "safe" level exists
it is instructive to explore the dimensions of this calculated
risk for the smallest possible indivisible daily dose. Using the
calculated risk value and assuming similar lifetime exposure
to 2,3,7,8-TCDD for the entire current population of the
world indicates that there would be less than 1 in a 100,000
chance of even a single case of cancer arising from that
infinitesimal level of exposure. From another perspective,
the calculated risk value indicates that all humans who have
ever lived on the planet could have been exposed at this
infinitesimal level without ever producing a single case of
cancer in the history of the human race.
This analysis does not attempt to consider the current
levels of exposure to 2,3,7,8-TCDD nor to evaluate what
risk levels may be associated with those particular human
exposure levels because different mechanisms likely apply.
Furthermore, this calculation for a hypothetical infinitesimal
exposure neither supports nor refutes arguments on the
contentious issues surrounding the human health
significance of 2,3,7,8-TCDD as an environmental
contaminant. However, it does illustrate that there is a
133 Steve E. Hrudey and Daniel Krewski, Is There a Safe Level of Exposure to a
Carcinogen? Envir. Sci & Technol. (in press 1995).
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quantifiable low level of exposure, which most reasonable
individuals would likely find to be below their own worry
threshold. [Note omitted.]
Hopefully, this kind of common sense analysis will be instrumental in
demystifying the science issues surrounding risk assessment which
should, in turn, help us improve our environmental decision making.
Alternative Approaches to Health Risk Assessment
Some environmentalists and politicians have questioned the
acceptability of risk assessment as a policy tool. The reason is that the
mere use of risk assessment is considered an admission that a certain
amount of risk is acceptable, while the imposition of any risk is unlawful
under certain statutes and unethical in many circumstances.1 3 4 This
issue has been difficult for policy makers to refute, but it assumes
enough discretionary monies are available to eliminate most risks,
including those from unwanted man-made chemicals. Perhaps the key
point raised by the environmental community is that alternatives to risk
assessment are worthy of continued discussion.
One alternative is technology-based approaches. This has, in fact,
been adopted in the 1992 Amendments to the U.S. Clean Air Act.
Another is to ban substances or legislate prohibitions on industrial
chemical emissions. Both approaches rely exclusively on hazard
identification and are very dependent on the skills of analytical
chemists since any measurable quantity could initiate action. In support
of this approach, some have argued that bans are the only successful
means to significantly reduce environmental risks. 13 5 Bans on the
chemicals DDT, PCB and lead in gasoline are often identified as major
success stories.
A third alternative to risk assessment, that appeals to some
environmentalist groups, is 'to adopt simpler rules for conducting health
assessments. For example, the European approach involves applying a
safety or uncertainty factor to the no-observed-effect level from the
best animal study and assume that this will prevent the adverse
effect. 136 This scheme places an equal weight on both carcinogenic and
134 Silbergeld, supra note 18.
135 Commoner, supra note 124.
136 U.S. Congress, Office of Technology Assessment (OTA), Researching Health
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non-carcinogenic chemicals. The advantage is that it is fast and
inexpensive, but a perceived disadvantage is that it concedes that some
level of exposure is probably safe for virtually all persons. In California
and a few other states in the U.S., risk assessment methods have been
standardized so that they can be conducted rapidly and inexpensively.
This, too, can promote or introduce many other scientific problems
because all the data are often unaccounted for.
A fourth alternative some have advocated relies upon public pressure
to minimize hazards. This approach has been used in several states in
the 1980's and has been argued to be highly effective. The best
documented approaches are California's Proposition 65 and
California's Assembly Bill AB-2588, wherein acceptable levels of
exposure were established using a single method, and any entity that
appears to expose persons above these levels must report both to the
agency and to exposed persons. 13 7 Sending letters of notification to
potentially affected persons is widely considered effective for
encouraging chemical users to minimize or eliminate emissions. This
sidesteps the many scientific problems with risk assessments by using
public pressure to prioritize hazards. Many within the environmental
community believe that this approach is quite workable.
Conclusions
In 1994, the U.S. spent nearly $190B to improve the
environment. 13 8 This is expected to increase about 7% annually until
the turn of the century. In all other countries, approximately $400B
more was spent in 1994 to tackle similar environmental problems. Yet,
even this is generally considered inadequate to address the concerns of
citizens virtually everywhere. Due to competing pressures for limited
funds, most nations are giving serious consideration to adopting risk-
assessment techniques to prioritize environmental agendas. For
example, nearly twenty proposals regarding the use of risk assessment as
a tool for conducting risk/benefit analyses were debated in the U.S.
Congress in 1993-95.139
Risks (1993).
137 Copeland et al. (1994), supra note 17.
138 Center for Risk Analysis, supra note 7 and Carnegie Commission, supra note 8.
139 See, e.g., Linda-Jo Schierow, Comparison of Environmental Risk Provisions in
the 103d Congress, 5 Risk 283 (1994).
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The scientific underpinnings of about twenty years of health risk
assessment practice and the implications for environmental policy have
been discussed in more than 600 peer-reviewed and published papers,
providing a wealth of information to other countries now in the process
of evaluating whether to use risk assessment to resolve difficult
environmental issues. Without question, other countries can learn from
the U.S. experiences, saving themselves billions of dollars spent as a
result of well-intended, but misguided, decisions made during the early
years of the environmental revolution. 14 0
In spite of numerous scientific or methodological uncertainties,
properly conducted risk assessments can provide reasonably accurate
predictions of the exposure of various populations and relatively
accurate estimates of the magnitude of health risk (except, perhaps, for
carcinogens). 14 1 Risk-assessment procedures have matured a great deal
over the past ten years. Use of less rigid approaches to interpreting the
significance of animal bioassay data should produce much more
defensible hazard identifications in the coming years. Biologically-
based disposition and cancer models should provide better estimates of
the actual human cancer risk at low levels of exposure, thus improving
the dose-response segment. Reliance on worst-case exposure scenarios is
no longer necessary in light of better information on specific exposure
parameters and more sensitive techniques for measuring concentrations
of contaminants in the environment. The use of Monte Carlo
techniques has revolutionized the practice of exposure assessment and
soon will change the practice of dose-response analysis. New and highly
sensitive analytical procedures will permit us to assay hair, blood, urine,
adipose and other biologic media to validate the reasonableness of the
exposure estimates. Statistical procedures to account for the
distribution of various factors within exposed populations will almost
certainly be integral to future risk assessments.
Our awareness of numerous scientific uncertainties, as well as
knowledge of how to best characterize them, will almost certainly lead
to more credible health risk assessments that will be more useful to risk
managers worldwide. If refinements are incorporated into future risk
140 Barnes, supra note 10; Viscusi, supra note I and EPA, supra note 12.
141 Paustenbach, supra note 17 and Lavy et al., supra note 36.
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assessments and are used to establish acceptable levels of chemical
exposure, scarce financial resources can be devoted to problems that,
when resolved, will yield the largest improvement in public health.
For these reasons, the EPA's Science Advisory Board (SAB) 142 and
the NAS 14 3 have promoted the routine use of quantitative risk
assessment in regulatory decision making. It appears that Australia,
New Zealand, Canada, the European community, countries in the
Pacific Rim and others will derive significant benefit from studying the
costly learning curve through which the U.S. has passed.
Appendix: Health Risk Assessment in Other Countries
The application of health risk assessment is growing rapidly in many
countries. It is not possible to discuss each, but a brief review of
directions that some are following will illustrate the range of approaches
being considered or implemented.
One major difference between the U.S. and other countries is how
carcinogens are evaluated and regulated. In countries such as the United
Kingdom and Germany, that rely primarily on expert judgments,
chemical carcinogens are regulated using a case-by-case approach.
Known or suspected chemical carcinogens are subjected to an individual
review that considers both the mechanism of action and the
epidemiology data. Risk assessment usually involves the formation of
expert advisory committees that make the decisions regarding exposure
standards or regulations, rather than an agency. The advisory body
commonly uses a "weight-of-the-evidence" approach, in which all of the
available information and test data are used to formulate a scientific
position for consideration as the basis for regulatory decision. This
approach has historically been poorly received in the U.S. due to
pressure to establish public policy that errs considerably on the side of
safety. In the wake of unrelenting financial pressure from competing
social needs, and the European experience, the weight-of-evidence
approach has gained momentum within EPA in recent years.
142 EPA, supra note 8.
143 NAS, supra note 3.
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Australia and New Zealand
Australia and New Zealand are in the fortunate position of being
able to learn from experience elsewhere. 14 4 Although incomplete, a
comparison of the U.S. and Australian practices has recently been
published. 145 With regard to contaminated lands, five characteristics
seem to differentiate Australian soil clean-up guidelines from most of
those adopted in the U.S., the Netherlands, and elsewhere. These seem
to have resulted from a careful attempt to avoid the deficiencies in
earlier efforts. First, there is a premise that a balance always exists
between cost and benefit. For example, recent risk-assessment
guidelines suggest that a complete clean-up of contaminated sites may
not always be technically achievable and that the benefits of full or
partial clean-up may be outweighed by the costs to society. 14 6
Second, there is a commitment to use risk assessment to help
identify the most appropriate level of clean-up. According to recent
guidelines, a contaminated site should be cleaned as necessary to
minimize short- and long-term, on- and off-site, risks. 14 7 To
accomplish this, there is an emphasis on flexibility to allow the most
logical solution to be selected and implemented. For example,
regulators are encouraged to consider that it may be appropriate in
cases where there is no threat to human health and the environment to
accept a strategy of containing contaminants or using planning controls
to limit site use. As a consequence, a fourth characteristic, unlike
policies adopted elsewhere, is recognition that it may be much less
expensive, and therefore wiser, to wait for new technologies to be
developed to address particularly difficult environmental problems.
Finally, health risk assessment guidelines in Australia and New
Zealand clearly attempt to combine both the human and environmental
risks when addressing chemical contamination. The emergence of
ecological risk assessment worldwide appears to be gaining greater
144 National Health and Medical Research of Australia and New Environmental
Council, Australian Guidelines for the Assessment and Management of Contaminated
Sites (1990).
145 Kenneth M. Murchison, Environmental Law in Australia and the U.S.: A
Comparative Overview (two parts), 6 Environ. Plan. L J. 179 and 8 Environ. Plan.
LJ. 254 (1994).
146 Ossama El Saadi & Andrew Langley, The Health Assessment and Management
of Contaminated Sites. (South Australian Health Commission 1991).
147 Australian Guidelines, supra note 144.
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recognition than in the U.S. due, in part, to increased concern about
preserving our natural resources and the rapidly growing eco-tourism
industry which may well become a central part of some economies.
Canada
In 1988, enactment of the Canada Environmental Protection Act
(CEPA) created a mandate for carrying out risk assessments. 14 8 CEPA
and other recent developments have led to a number of nationally or
provincially developed exposure standards in Canada. Historically,
Canadian regulatory bodies have relied on exposure standards and
occupational exposure limits generated by other countries (e.g.,
Sweden, The Netherlands, Denmark and the U.S.) and organizations
(e.g., World Health Organization and the American Conference of
Governmental and Industrial Hygienists). In most instances, the
Canadian government has not considered using cancer potency factors
and reference doses developed by the EPA because they see these
figures as overly conservative. In general, risk-assessment decisions in
Canada are performed on a case-by-case basis. In each case, scientists
use a weight-of-evidence approach (rather than strict regulatory policy)
to select the most appropriate dose-extrapolation model.
In regulating chemical substances, the responsible Canadian
authorities consider the probable carcinogenic mechanism of action
when making decisions about acceptable levels of exposure. For
example, for nongenotoxic chemicals, uncertainty factors are added to
the no-observed-adverse-effect level (NOAEL) to calculate a tolerable
daily intake similar to the U.S. acceptable daily intake (ADI).
Conversely, for genotoxic carcinogens, regulators select one of several
methods under a policy aimed to reduce health risks by as much as
possible. At this time, the approach used to assess genotoxic carcinogens
involves estimating an exposure-potency index (EPI). This index
compares the expected exposure of a population with an estimate of the
carcinogenic potency of the chemical. The potency estimate is derived
from epidemiologic or animal data with the objective of identifying the
dose that would cause a carcinogenic response in 5% of the test
subjects.
148 OTA, supra note 136.
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The European Community
For several years, the European Community (E.C.) has worked
toward the harmonization of health, safety and environmental
regulations, to reduce competitive imbalances among member countries
and to prevent regulations from acting as trade barriers. The central
goal remains the protection of public health and environmental
quality. 14 9 In an attempt to identify the optimal cost/benefit
relationship, the E.C. has adopted risk assessment to determine
acceptable standards of chemical exposure and levels of risk, and to
identify appropriate chemical-testing procedures. The E.C. procedure
for chemical testing was an important advance in harmonizing
chemical-assessment guidelines of various member nations. The 1967
E.C. directive has served as a model for environmental regulation in
other countries and international organizations, e.g., OECD. 150
European legislation pertaining to risk assessment has been mainly
directed at chemical safety, pesticide residues, food additives and
occupational exposures. Most countries mandate both qualitative and
quantitative risk assessments, depending on the type of chemical and
usage. A common characteristic of most directives passed or proposed
in those fields is that the member states or individual employers are
responsible for performing risk assessments, not the regulatory agencies.
Scientific experts are used throughout, both by those performing risk
assessments and by various agencies during the review process.
Although as recently as 1993 there was significant optimism that
roughly similar risk-assessment procedures would be used throughout
Europe, this appears unlikely in the near future.
Germany
In Germany, the use of quantitative risk assessment is relatively new
to regulation. Previously, regulatory authorities did not quantify the
risk from exposure to carcinogens or other toxic substances because the
inherent acceptance of a quantitative risk estimate did not comply with
principles established within German environmental laws. 1 5 1 The
149 Commission of the European Communities, Chemical Risk Control in the
European Community (1987).
150 Organisation for Economic Cooperation and Development, Environmental
Directorate, OECD Cooperative Risk Reduction Activites (1992).
151 R. Turck, Nature, Conservation and Nuclear Safety (Fed. Ministry Environment)
(1993).
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notion of allowing any degree of risk to humans diverges from the
German emphasis on eliminating any danger to public health, a basic
objective of their environmental regulations. To date, risk assessments
have infrequently been used in Germany to resolve important
environmental issues. As the need for a quantitative form of risk
assessment has become increasingly necessary, regulators have
conducted several surveys of the methodologies used by other countries
and have selectively adopted some of them. The methodologies of the
EPA have had a strong impact on German regulatory committees
exploring the process, but they have not mandated its use. Believing
that a case-by-case approach to assessing chemicals leads toward more
accurate estimations of risk, the German regulators have advocated
using flexible, rather than policy-driven, approaches.
Although German authorities do not widely practice risk
assessment, known human carcinogens are strictly regulated. To date,
known human carcinogens have been subjected to stringent regulations
focusing partially on the best available technology (BAT) or, in the case
of drinking water regulations, on international E.C. directives. It is also
commonplace for decisions concerning the regulation of chemical
carcinogens and other hazardous chemicals in Germany to be made by
multipartite expert committees on a case-by-case basis. Typically, an
expert committee relies upon a NOAEL/ADI approach to identify
acceptable levels of exposure to noncarcinogenic chemicals.
The Netherlands
In the Netherlands, and in most other European nations, regulators
use the term quantitative risk assessment (QRA) as synonymous with
low-dose modeling conducted by risk assessors in the U.S. The QRA
approach to low-dose modeling is used to estimate the probability of
risks to human health from carcinogens that have been definitively
categorized as genotoxic. The method is currently used by all Dutch
agencies, but the model varies somewhat based on knowledge about the
mechanism of action of the chemical. 152
In the Dutch risk-assessment process, scientists initially evaluate a
chemical to determine its genotoxicity. Subsequently, they use
information about functional effects and chemical structure, the results
152 OTA, supra note 136.
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of bioassays, and other relevant data to. reduce the uncertainties relating
to the genotoxic potential in humans. When it is impossible to
eliminate completely the risk of exposure to a genotoxic carcinogen, the
Dutch approach relies upon a very simple linear extrapolation model to
determine a dose-response value for human exposure. 153 A simple
linear extrapolation of animal data to humans is considered a very
conservative approach, as the metabolic rate of humans is lower than
that of animals and is also inversely proportional to age and weight.
DNA repair processes appear to be proportional to body weight, and
the sensitivity of man to known human carcinogens is about equal to
that of experimental animals. 1
54
Like most other European countries, virtually all of the safe levels of
exposure for a nongenotoxic carcinogen identified in regulations are
based on a NOAEL divided by a safety factor of ten to 1,000,
depending on the amount of uncertainty in the data. The resulting
value represents an acceptable daily intake for the substance.
Dutch regulators have distinguished themselves by having
developed a number of innovative methods for assessing the hazards
posed by contaminated soils. 15 5 The Dutch standards are probably the
most widely cited soil standards in the world.156 They recently added
guidelines for air, groundwater, surface water and sediment. In support
of these efforts, they have also conducted a number of research efforts
to evaluate the uptake of soil by humans and the environmental fate of
the contaminants.
Scandinavia
In controlling toxic substances, authorities in Denmark recognize
different carcinogenic mechanisms and use the safety-factor approach
for nongenotoxic carcinogens and noncarcinogens. The basic
toxicological data used to generate exposure standards are generally the
153 Richard Kroes, Animal Data: Interpretation and Consequences in Environmental
Carcinogenesis (P. Emmelot & E. Kriek, eds. 1979).
154 Richard Kroes, Contribution of Toxicology Toward Risk Assessment of
Carcinogens, 60 Arch. Toxicol. 224 (1987).
155 Joop H. van Wijnen, P. Clausing & B. B. Brunekreef, Estimated Soil Ingestion
by Children, 51 Environ. Res. 147 (1990) and Joop H. van Wijnen, Health Risk
Assessment of Soil Contamination (1990).
156 M. E. J. Van der Weiden, Environmental Quality Objectives in the Netherlands
(1994).
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same across the various regulatory agencies, but the manner in which
the data are used differs according to the problem being addressed.
Danish regulators also use a case-by-case approach when evaluating data
for a toxic substance, although reliance on expert advisory committees
is not as extensive in Denmark as in other countries, 15 7 such as the
U.K. 158 Currently, Denmark's National Food Agency of the Ministry
of Health administers regulations for food additives. ADIs are
determined using principles outlined by the Joint FAO/WHO
Committee on Food Additives as the basis for permitted use levels. 159
Using such an approach, Denmark has banned all food additives that
are classified as genotoxic carcinogens.
Regulators in Denmark employ risk-assessment techniques only to a
limited extent when determining exposure standards for carcinogens.
In cases where new chemicals may be substituted for a suspected
carcinogen, an assessment is required to examine whether exposure can
be eliminated effectively. Low-dose extrapolation models are used to
estimate risk when a nonthreshold genotoxic carcinogen cannot be
replaced by another chemical. 160
In Sweden, the EPA sets exposure standards for a variety of
carcinogenic and noncarcinogenic chemicals and uses classic risk-
assessment methods to assess health risks for industrial emissions. 16 1
Like other European countries that use risk assessment, regulators
consider carcinogens with a pronounced genotoxic mechanism as prime
candidates for careful analysis. As part of that process, the Swedish EPA
uses mathematical models to extrapolate from animals exposed to high
doses of carcinogens to predict the effects on humans exposed to lower
doses. The agency also evaluates the carcinogens using a case-by-case
approach in which each chemical is assessed individually, as opposed to
the more generic approach common in U.S. regulatory agencies that
follow fairly strict guidelines.
157 L. Dragsted, Low Dose Extrapolation of Data from Animal Bioassays, in Risk
Managements and Risk Assessment in Different Sectors of Denmark 77 (1992).
158 Department of Health (U.I), Comm. on Carcinogenicity of Chemicals in Food,
Guidelines for Evaluation of Chemicals for Carcinogenidty (1991)
159 Dragsted, supra note 155.
160 Id.
161 OTA, supra note 136.
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Swedish regulators use a weight-of-the evidence approach to
evaluate a chemical's carcinogenic potential. Like most other European
countries, genotoxic carcinogens are typically regulated to ensure the
lowest possible levels of exposure; for nongenotoxic chemicals, safe
levels of exposure are identified from a NOAEL or lowest-observed-
adverse-effect level (LOAEL) and a safety factor applied based on the
level of uncertainty in the available information. These ADIs are then
used to calculate maximum residue levels of pesticides in food and
occupational exposure limits.
United Kingdom
In the U.K., risk-assessment methods have not been used to
establish an environmental agenda or to regulate specific chemicals.
Regulatory agencies do not use risk-assessment models to generate a
probability for the risk of cancer from exposure to certain chemicals.
U.K. regulators place little reliance on the quantitative assessment of
carcinogens because they believe that the statistical models used to
extrapolate dose-response effects from animals to humans are not
valid. 162
Papers list several reasons for U.K. skepticism of commonly-used
U.S. dose-extrapolation models. First, a linear low-dose model has yet
to be validated. Second, the bioassay data used to derive a low-dose
model of chemical carcinogenicity are incomplete. Third, the low-dose
models are based more on mathematical assumptions than established
biochemical mechanisms; consequently, risk estimates vary widely
depending on the model used. Last, models give an unjustified
impression of precision, given the approximations and assumptions
upon which they are based. 1
63
The regulation of chemical carcinogens in the U.K. is based on
mechanistic considerations. For example, if a chemical acts by a
genotoxic mechanism, regulators assume, as a matter of prudence, that
the compound does not have a threshold. If a nongenotoxic mechanism
is known to be involved, regulators consider it possible to identify a safe
level of exposure. 16
4
162 van Wijnen, supra note 155.
163 U.K., supra note 158.
164 OTA, supra note 136.
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Chemicals displaying genotoxicity are evaluated using expert
judgment and a weight-of-the-evidence approach. In evaluating such
compounds, experts consider all available evidence (including human
data, animal data, mutagenicity data and structure/activity
relationships). If they conclude that the compound should be
considered a potential human carcinogen that acts by a genotoxic
mechanism, they recommend action to reduce levels to as low as is
reasonably practical or to eliminate it entirely. For suspected
carcinogenic compounds operating through a well-understood
nongenotoxic mechanism, researchers evaluate animal studies to
determine the NOAEL, which is then divided by a safety factor to
derive an ADI. The safety factor reflects the uncertainties of
extrapolating from animals to humans and of variation among
individuals. 165 ADIs are also used to calculate maximum residue levels
for pesticides on food.
165 U.K., supra note 158.
